

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Interventional procedure overview of ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Uterine fibroids are non-cancerous growths on the inside or outside of the womb (uterus). In this procedure, the woman lies face down with an ultrasound scanning device placed on the skin of the abdomen immersed in water. This scans the womb to show where the fibroids are. A separate device is used to deliver a precisely focussed dose of high-intensity ultrasound energy through the skin of the abdomen (transcutaneous). This heats the fibroid until most or all of it is destroyed. The woman may have to lie still for up to 3 hours during the procedure. The aim is to reduce symptoms caused by the fibroids.

Contents

[Introduction](#)

[Description of the procedure](#)

[Efficacy summary](#)

[Safety summary](#)

[The evidence assessed](#)

[Validity and generalisability of the studies](#)

[Existing assessments of this procedure](#)

[Related NICE guidance](#)

[Additional information considered by IPAC](#)

[References](#)

[Literature search strategy](#)

[Appendix](#)

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Introduction

The National Institute for Health and Care Excellence (NICE) prepared this interventional procedure overview to help members of the interventional procedures advisory committee (IPAC) make recommendations about the safety and efficacy of an interventional procedure. It is based on a rapid review of the medical literature and specialist opinion. It should not be regarded as a definitive assessment of the procedure.

Date prepared

This overview was prepared in October 2018.

Procedure name

- Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Specialist societies

- British Society of Interventional Radiology
- Royal College of Obstetricians and Gynaecologists.

Description of the procedure

Indications and current treatment

Uterine fibroids are benign tumours of the uterine wall. They can be asymptomatic or cause symptoms including menorrhagia, intermenstrual bleeding, pelvic pressure or pain, and urinary incontinence. They can be associated with fertility problems and miscarriage.

Treatment depends on whether the fibroids cause symptoms, and if the person wishes to have children in the future. For symptomatic fibroids, treatment options include medications and surgery. Surgery includes hysterectomy, myomectomy, uterine artery embolisation, endometrial ablation techniques, MRI-guided focussed ultrasound and myolysis.

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

What the procedure involves

Ultrasound-guided high-intensity transcutaneous focused ultrasound (HIFU) for symptomatic uterine fibroids is done with the patient lying face down, with the abdominal wall immersed in degassed water. Intravenous sedation may be used to help minimise body movement. A urinary catheter is inserted to keep the bladder empty during the procedure. Continuous sonographic imaging is used to identify the fibroid(s) with a real-time diagnostic ultrasound scanner integrated into the centre of a therapeutic ultrasound transducer. After the target fibroid has been confirmed, it is ablated by high-intensity ultrasound energy. The patient may have to lie still for up to 3 hours. Ultrasound-guided HIFU uses grayscale or echogenicity changes to determine the adequacy of ablation. After treatment, imaging (by ultrasound or MRI scan) is used to evaluate the volume of the fibroid ablated.

Outcome measures

Non-perfused volume (NPV) ratio

This is the sum of the non-perfused volume (volume that was not enhanced in the contrast-enhanced MRI) of all treated fibroids divided by the volume of all uterine fibroids, treated and untreated. It is indicative of ablation efficiency.

Efficacy summary

Non-perfused volume (NPV) ratio

In a retrospective case series of 27,053 patients including 17,402 patients with uterine fibroids, the median NPV ratio for patients with uterine fibroids was 85% (interquartile range 75% to 94%).¹

In a retrospective case series of 9,988 patients with uterine fibroids (7,438 patients) or adenomyosis (2,549 patients), the mean NPV ratio (\pm standard deviation [SD]) for patients with uterine fibroids was 83.1% \pm 15.6%.² In the same study the technical success rate (defined as a NPV ratio over 25% of the tumour volume) in patients with uterine fibroids was 98% (7,319/7,439).²

In a prospective non-randomised cohort study of 2,411 patients with fibroids having ultrasound-guided high-intensity focused ultrasound (USgHIFU) (n=1,353), myomectomy (n=586) or hysterectomy (n=472), the mean NPV ratio for USgHIFU was 87%.³

In a retrospective comparative study of 442 patients with anteverted (n=221) or retroverted uterus (n=221) having USgHIFU, the mean NPV ratio (\pm SD) after the procedure was statistically significantly greater in the anteverted uterus group

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

(87.7% ± 11.8%) compared with the retroverted uterus group (85.2% ± 18.7%, p=0.00).⁵

In a prospective comparative study of 94 patients with symptomatic uterine fibroids treated with USgHIFU or MRI-guided HIFU (MRlgHIFU) there were statistically significantly more patients in the USgHIFU group with an NPV ratio of 100% at 6 months compared with the MRlgHIFU group (43% (22/51) compared with 23% (10/43), p=0.031). In the same study, the proportions of patients with an NPV ratio of 90% to 99% at 6 months were 18% (9/51) compared with 23% (10/43) respectively for USgHIFU and MRlgHIFU and the proportions of patients with an NPV ratio of less than 90% at 6 months were 39% (20/51) compared with 53% (23/43) respectively.⁸

Fibroid volume shrinkage

In a retrospective case series of 189 nulliparous women, the mean uterine fibroid volume shrinkage was 58.0% ± 31.3% after USgHIFU treatment (the findings referred to only the largest fibroid in cases of multiple fibroids).⁶

In the prospective comparative study of 94 women with symptomatic uterine fibroids treated with USgHIFU or MRlgHIFU, the mean fibroid volume reduction at 6 months (for patients with a NPV ratio of 100%) was 52.7% ± 11.4% in the USgHIFU group compared with 59.1% ± 9.0% in the MRlgHIFU group (no statistically significant difference between groups).⁸

Re-intervention rate

In the prospective non-randomised cohort study of 2,411 patients with fibroids having USgHIFU, myomectomy or hysterectomy, the re-intervention rate (defined as any need for recurrent treatment of fibroid-related symptoms, assessed for the HIFU and myomectomy groups only) was 1% (14/1,353) in the USgHIFU group compared with 0% (0/586) in the myomectomy group at 1 year. The re-interventions were: one second HIFU treatment, 12 myomectomies and 1 hysterectomy.³

Reduction of uterine fibroid symptoms

In the prospective non-randomised cohort study of 2,411 women with fibroids having USgHIFU, myomectomy or hysterectomy, the mean uterine fibroid symptoms (UFS) scores (scale ranges from 0 to 100 with higher scores indicating more serious symptoms) decreased statistically significantly more in the USgHIFU group than in the myomectomy group at 6 months (difference from baseline: -9.84 ± 13.37 compared with -8.23 ± 13.10, p=0.002) and at 12 months (-12.17 ± 9.71 compared with -9.71 ± 13.69, p=0.000).³

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

In the retrospective case series of 189 nulliparous women, 84% (159/189) of women had clinical symptoms before USgHIFU treatment and the symptoms remission rate was 89% (141/189) after treatment. ⁶

In a prospective comparative study of 130 patients with symptomatic uterine fibroids having USgHIFU (n=89) or laparoscopic myomectomy (n=41), the mean symptom scores assessing symptom improvement (11-point symptom score ranging from 5 (markedly worse) to +5 (markedly better)) were not statistically significantly different between groups at 1 month (3.3 compared with 3.1) or at 12 months (4.0 compared with 4.3). ⁷

In the prospective comparative study of 94 patients with symptomatic uterine fibroids treated with USgHIFU or MRlgHIFU, the mean symptom severity score in the USgHIFU group decreased from 25.3 ± 14.7 before the procedure to 15.1 ± 5.1 at 6 months compared with a change from 26.6 ± 4.3 to 14.6 ± 2.0 in the MRlgHIFU group (no statistically significant difference between groups at 6 months). ⁸

Quality of life

In the prospective non-randomised cohort study of 2,411 women with fibroids having USgHIFU, myomectomy or hysterectomy, the mean quality of life scores (scale ranges from 0 to 100 with higher scores indicating better quality of life) increased statistically significantly more in the USgHIFU group than in the myomectomy group at 6 months (difference from baseline: 9.61 ± 14.01 compared with 7.42 ± 12.83 , $p=0.001$) and at 12 months (12.89 ± 16.16 compared with 10.50 ± 15.33 , $p=0.008$). ³

In the prospective comparative study of 130 women with symptomatic uterine fibroids having USgHIFU (n=89) or laparoscopic myomectomy (n=41), the SF-36 scores (from 0 to 100 with higher scores indicating better function) for physical function, physical role, bodily pain, general health, vitality, social function, emotional role and mental health were similar between groups before the procedure. At 1 month, the SF-36 score for physical function had statistically significantly improved from 74.8 ± 24.9 to 88.4 ± 25.4 ($p < 0.001$) in the USgHIFU group only and the SF-36 score for mental health had statistically significantly improved from 61.2 ± 22.4 to 77.4 ± 19.4 ($p < 0.001$) in the myomectomy group only. Only SF-36 scores for emotional role and mental health were statistically significantly different between groups at 1 month (52.4 ± 44.0 compared with 70.3 ± 35.5 [$p=0.02$] and 66.4 ± 18.0 compared with 77.4 ± 19.4 [$p=0.002$] respectively). At 12 months, all the SF-36 scores had statistically significantly improved from baseline in the USgHIFU group ($p < 0.001$), and in the myomectomy group, only general health and emotional role did not statistically significantly change from baseline. There were no statistically significant differences in the SF-36 scores between groups at 12 months. ⁷

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Pregnancy rate

In the prospective non-randomised cohort study of 2,411 women with fibroids having USgHIFU, myomectomy or hysterectomy, the pregnancy rate 1 year after the procedure was 2% (28/1,353) in the USgHIFU group compared with less than 1% (4/586) in the myomectomy group and 0% (0/472) in the hysterectomy group.³

In the retrospective case series of 189 nulliparous women, the pregnancy rate was 69% (131/189) after USgHIFU treatment with a mean interval between USgHIFU treatment and pregnancy of 12.3 ± 9.9 months. The spontaneous pregnancy rate was 95% (125/131) and the pregnancy rate through assisted reproductive technology was 5% (6/131). Among women with a history of infertility, the pregnancy rate after USgHIFU was 20% (9/45). At the time of analysis, the birth rate was 70% (93/133), there were 14% (19/133) ongoing pregnancies and the abortion rate was 16% (21/133) with 13% (17/133) of spontaneous abortions.⁶

Patient satisfaction

In the prospective comparative study of 130 women with symptomatic uterine fibroids having USgHIFU (n=89) or laparoscopic myomectomy (n=41), the willingness rate to recommend treatment to a friend was not statistically significantly different between groups (89% [74/83] compared with 92% [36/39]).⁷

Sexual function

In the prospective RCT of 100 patients who had USgHIFU (n=48) or myomectomy (n=52) for symptomatic uterine fibroids, the rate of sexually active patients 3 months after USgHIFU was 100% compared with 96% after myomectomy and 100% in both groups at 6 months. In the same study, the mean brief index of sexual functioning (BISF) scores (higher score represents more favorable sexual functioning) statistically significantly improved from baseline to 6 months in both groups from 24.64 ± 6.64 to 26.67 ± 5.15 for USgHIFU and from 24.91 ± 6.51 to 26.82 ± 5.72 for myomectomy ($p < 0.05$). There was no statistically significant difference between groups at 6 months.⁴

Return to work or daily activities

In the prospective non-randomised cohort study of 2,411 women with fibroids having USgHIFU, myomectomy or hysterectomy, the mean time to return to work was statistically significantly shorter in the USgHIFU group (4 days) than in the myomectomy group (24 days) and in the hysterectomy group (29.5 days); $p < 0.001$ for the comparison between USgHIFU and surgery.³

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

In the prospective RCT of 100 patients who had USgHIFU (n=48) or myomectomy (n=52) for symptomatic uterine fibroids, the time to return to normal daily activities was statistically significantly shorter in the USgHIFU group (7 days) compared with the myomectomy group (15 days), $p < 0.001$. In the same study, the time to out-of-bed activity was also statistically significantly shorter in the USgHIFU group (1 hour) compared with the myomectomy group (48 hours), $p < 0.001$.⁴

In the prospective comparative study of 130 women with symptomatic uterine fibroids having USgHIFU (n=89) or laparoscopic myomectomy (n=41) there were statistically significantly less lost workdays, days late for work, days spent in bed and days without usual activities in the USgHIFU group compared with the myomectomy group ($p < 0.001$).⁷

Treatment time

In the prospective comparative study of 94 women with symptomatic uterine fibroids treated with USgHIFU or MRlgHIFU, the treatment time for USgHIFU was statistically significantly shorter (114.4 ± 39.2 minutes) compared with MRlgHIFU (174.5 ± 42.2 minutes), $p = 0.021$.⁸

Hospital length of stay

In the prospective non-randomised cohort study of 2,411 women with fibroids having USgHIFU, myomectomy or hysterectomy, the mean hospital length of stay was statistically significantly shorter in the USgHIFU group (4 days) than in the myomectomy group (9 days) and in the hysterectomy group (10.5 days); $p < 0.001$ for the comparison between USgHIFU and surgery.³

In a prospective RCT of 100 patients who had USgHIFU (n=48) or myomectomy (n=52) for symptomatic uterine fibroids, the hospital length of stay was statistically significantly shorter in the USgHIFU group (1 day) compared with the myomectomy group (4 days), $p < 0.001$.⁴

In the prospective comparative study of 130 women with symptomatic uterine fibroids having USgHIFU (n=89) or laparoscopic myomectomy (n=41), the mean length of hospital stay was statistically significantly shorter in the USgHIFU group (2.9 days) compared with the myomectomy group (6.2 days) ($p < 0.001$).⁷

Safety summary

Skin burn

Skin burn was reported in less than 1% of patients (26/17,402) with uterine fibroids after USgHIFU treatment, in a retrospective case series of 27,053 patients including 17,402 patients with uterine fibroids.¹

Skin burn was reported in less than 1% (26/9,988) of all patients with uterine fibroids or adenomyosis within 14 days of USgHIFU treatment in the retrospective case series of 9,988 patients.²

Second-degree skin burn was reported in less than 1% (3/1,353) of patients in the USgHIFU group and in none of the patients in the surgery group (having myomectomy or hysterectomy) after treatment, in a prospective non-randomised cohort study of 2,411 women with fibroids having USgHIFU (n=1,353), myomectomy (n=586) or hysterectomy (n=472). In the same study, first to second degree skin burn was reported in less than 1% (2/1,353) of patients in the USgHIFU group and in none of the patients in the surgery group.³

Skin burn was reported in 25% (12/48) of patients who had USgHIFU compared with none of the patients who had myomectomy (n=52) in a prospective RCT of 100 patients with symptomatic uterine fibroids (p<0.001).⁴

A 'hot' skin sensation was reported in 48% of patients during the USgHIFU procedure in the anteverted uterus group (n=221) compared with 27% of patients in the retroverted uterus group (n=221) in a retrospective comparative study of women (p=0). In the same study, skin burn after the USgHIFU treatment was reported in none of the patients with anteverted uterus and in 2% (5/221) of patients with retroverted uterus (p=0.031); the patients were treated by resection.⁵

Skin burn was reported in 13% (12/89) of patients after USgHIFU and in none of the patients after laparoscopic myomectomy (n=41) in a prospective comparative study of 130 women with symptomatic uterine fibroids having USgHIFU or laparoscopic myomectomy (p<0.001).⁷

Pain

Lower abdominal pain was reported in 2% (225/9,988) of all patients with uterine fibroids or adenomyosis within 7 days of USgHIFU treatments in the retrospective case series of 9,988 patients.²

Lower abdominal pain was reported in 69% of patients during the USgHIFU procedure in the anteverted uterus group (n=221) compared with 58% of patients in the retroverted uterus group (n=221) in the retrospective comparative study of
IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

442 women ($p=0.012$). In the same study, groin pain was reported in 3% of patients during the procedure in the anteverted uterus group compared with 13% of patients in the retroverted uterus group ($p=0$). After the procedure, lower abdominal was reported in 17% of women with anteverted uterus compared with 20% of women with retroverted uterus (no statistically significant difference between groups).⁵

Mild pain in the lower abdomen was reported in 9% (2/22) of patients with completely ablated fibroids treated with USgHIFU compared with 30% (3/10) of patients treated with MRlgHIFU in the prospective comparative study of 94 women with symptomatic uterine fibroids treated with USgHIFU or MRlgHIFU.⁸

Pain (no further details specified) was reported in 73% (35/48) of patients who had USgHIFU compared with 54% (28/52) of patients who had myomectomy in the prospective RCT of 100 patients with symptomatic uterine fibroids ($p=0.048$).⁴

Pain or discomfort (no further details specified) was reported in 45% (40/89) of patients after USgHIFU and in 41% (17/41) of patients after laparoscopic myomectomy in the prospective comparative study of 130 women with symptomatic uterine fibroids having USgHIFU or laparoscopic myomectomy (no statistically significant difference between groups).⁷

Leg pain was reported in less than 1% of patients (10/17,402) with uterine fibroids after USgHIFU treatment, in the retrospective case series of 27,053 patients including 17,402 patients with uterine fibroids.¹

Leg or buttock pain was reported in less than 1% (76/9,988) of all patients with uterine fibroids or adenomyosis within 3 months of USgHIFU treatment in the retrospective case series of 9,988 patients.²

Lumbar and sacrum pain was reported in 11% (150/1,353) of patients in the USgHIFU group compared with 13% (134/1,058) of patients in the surgery group in the prospective non-randomised cohort study of 2,411 women with fibroids having USgHIFU, myomectomy or hysterectomy. In the same study, numbness and pain in the lower limbs after treatment was reported in 3% (34/1,353) of patients in the USgHIFU group compared with 2% (18/1,058) of patients in the surgery group. Weakness in lower limb was reported in less than 1% (9/1,353) of patients in the USgHIFU group compared with 6% (62/1,058) of patients in the surgery group.³

Transient leg pain was reported in 12% of patients in the anteverted uterus group ($n=221$) compared with 14% of patients in the retroverted uterus group ($n=221$) during the USgHIFU procedure in the retrospective comparative study of 442 women (no statistically significant difference between groups). In the same study,

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

sciatic or buttock pain was reported in 39% of patients in the anteverted uterus group compared with 72% of patients in the retroverted uterus group ($p=0$). After the procedure, leg pain or numbness was reported in none of the patients with anteverted uterus compared with less than 1 % (1/221) of patients with retroverted uterus (no statistically significant difference between groups). Sciatic or buttock pain after the procedure was reported in 5% and 20% of women respectively ($p=0.001$).⁵

Mild pain in the lower back was reported in 5% (1/22) of patients with completely ablated fibroids treated with USgHIFU compared with none of the patients treated with MRlgHIFU in a prospective comparative study of 94 women with symptomatic uterine fibroids treated with USgHIFU or MRlgHIFU.⁸

Pain and distension of anus was reported in less than 1 % (11/1,353) of patients in the USgHIFU group compared with 4% (38/1,058) of patients in the surgery group in the prospective non-randomised cohort study of 2,411 women with fibroids having USgHIFU, myomectomy or hysterectomy.³

Vaginal bleeding or discharge

Vaginal bleeding was reported in less than 1% of patients (6/17,402) with uterine fibroids after USgHIFU treatment, in the retrospective case series of 27,053 patients including 17,402 patients with uterine fibroids.¹

Vaginal secretion was reported in 9% (874/9,988) of all patients with uterine fibroids or adenomyosis within 1 to 14 days of USgHIFU treatment in the retrospective case series of 9,988 patients.²

Vaginal bleeding or abnormal vaginal discharge was reported in 6% (3/48) of patients who had USgHIFU compared with 48% (25/52) of patients who had myomectomy in the prospective RCT of 100 patients with symptomatic uterine fibroids ($p<0.001$).⁴

Vaginal discharge was reported in 5% of women with anteverted uterus ($n=221$) after the USgHIFU procedure compared with 7% of women with retroverted uterus ($n=221$) in the retrospective comparative study of 442 women ($p=0.012$).⁵

Irregular vaginal bleeding or discharge was reported in 18% (16/89) of patients after USgHIFU and in 15% (6/41) of patients after laparoscopic myomectomy in the prospective comparative study of 130 women with symptomatic uterine fibroids having USgHIFU or laparoscopic myomectomy (no statistically significant difference between groups).⁷

Abnormal vaginal discharge was reported in 14% (3/22) of patients with completely ablated fibroids treated with USgHIFU compared with 20% (2/10) of

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

patients treated with MRIgHIFU in the prospective comparative study of 94 women treated with USgHIFU or MRIgHIFU.⁸

Heavy vaginal bleeding was reported in 1 patient with a submucosal fibroid in a case reports of 3 patients treated with USgHIFU, 8 months after the procedure. The patient was treated with blood transfusions, ulipristal and an emergency uterine artery embolisation.⁹

Genital tract infection was reported in 12% (11/89) of patients after USgHIFU and in 12% (5/41) of patients after laparoscopic myomectomy in the prospective comparative study of 130 women with symptomatic uterine fibroids having USgHIFU or laparoscopic myomectomy (no statistically significant difference between groups).⁷

Uterine infection or bleeding

Intrauterine infection was reported in less than 1% of patients (2/17,402) with uterine fibroids after USgHIFU treatment, in the retrospective case series of 27,053 patients including 17,402 patients with uterine fibroids.¹

Uterus bleeding was reported in less than 1% (24/9,988) of all patients with uterine fibroids or adenomyosis within 14 days of USgHIFU treatment in the retrospective case series of 9,988 patients.²

Uterine bleeding was reported in 7 % (88/1,353) of patients in the USgHIFU group compared with 21% (222/1,058) of patients in the surgery group in the prospective non-randomised cohort study of 2,411 patients with fibroids having USgHIFU, myomectomy or hysterectomy.³

Urinary retention

Urinary retention was reported in less than 1% of patients (7/17,402) with uterine fibroids after USgHIFU treatment, in the retrospective case series of 27,053 patients including 17,402 patients with uterine fibroids.¹

Urinary retention was reported in less than 1% (16/9,988) of all patients with uterine fibroids or adenomyosis within 7 days of USgHIFU treatment in the retrospective case series of 9,988 patients.²

Urinary retention was reported in less than 1% (2/1,353) of patients in the USgHIFU group compared with 2% (25/1,058) of patients in the surgery group in the prospective non-randomised cohort study of 2,411 patients with fibroids having USgHIFU, myomectomy or hysterectomy.³

Irritation sign of bladder or urinary retention was reported in 4% (2/48) of patients who had USgHIFU compared with 21% (11/52) of patients who had myomectomy

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

in the prospective RCT of 100 patients with symptomatic uterine fibroids (p=0.016).⁴

Urinary tract adverse event

Urinary tract adverse event was reported in 22% (20/89) of patients after USgHIFU and in 22% (9/41) of patients after laparoscopic myomectomy in the prospective comparative study of 130 patients with symptomatic uterine fibroids having USgHIFU or laparoscopic myomectomy (no statistically significant difference between groups).⁷

Hyperpyrexia

Hyperpyrexia was reported in less than 1% of patients (5/17,402) with uterine fibroids after USgHIFU treatment, in the retrospective case series of 27,053 patients including 17,402 patients with uterine fibroids. ¹

Fever was reported in less than 1% (4/9,988) of all patients with uterine fibroids or adenomyosis within 7 days of USgHIFU treatment in the retrospective case series of 9,988 patients.²

Fever that did not need treatment was reported in less than 1 % (2/1,353) of patients in the USgHIFU group compared with less than 1% (6/1,058) of patients in the surgery group in the prospective non-randomised cohort study of 2,411 patients with fibroids having USgHIFU, myomectomy or hysterectomy.³

Temperature of more than 38°C was reported in 2% (2/89) of patients after USgHIFU and in 10% (4/41) of patients after laparoscopic myomectomy on any 2 days after treatment in the prospective comparative study of 130 patients with symptomatic uterine fibroids having USgHIFU or laparoscopic myomectomy (no statistically significant difference between groups).⁷

Rehospitalisation more than 24 hours after the procedure

Rehospitalisation more than 24 hours after the procedure was reported in 3% (3/89) of patients after USgHIFU and in 2% (1/41) of patients after laparoscopic myomectomy in the prospective comparative study of 130 patients with symptomatic uterine fibroids having USgHIFU or laparoscopic myomectomy (no statistically significant difference between groups).⁷

Rapid fibroid enlargement

Rapid fibroid enlargement was reported in 2 patients after 12 USgHIFU treatments and 4 years after 1 USgHIFU treatment in a case reports of 3 patients treated with USgHIFU. Both patients were treated with a transabdominal myomectomy.⁹

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Other adverse events

The following adverse events were also reported in the literature:

Renal failure was reported in less than 1% of patients (4/17,402) with uterine fibroids after USgHIFU treatment, in the retrospective case series of 27,053 patients including 17,402 patients with uterine fibroids. ¹

Acute cystitis was reported in less than 1% of patients (3/17,402) with uterine fibroids after USgHIFU treatment, in the retrospective case series of 27,053 patients including 17,402 patients with uterine fibroids. ¹

Odynuria or haematuria was reported in less than 1% (52/9,988) of all patients with uterine fibroids or adenomyosis within 7 days of USgHIFU treatment in the retrospective case series of 9,988 patients.² Haematuria was reported in less than 1% (3/1,353) of patients in the USgHIFU group compared with 2% (18/1,058) of patients in the surgery group in the prospective non-randomised cohort study of 2,411 patients with fibroids having USgHIFU, myomectomy or hysterectomy.³

Bowel injury was reported in less than 1% of patients (3/17,402) with uterine fibroids 4 to 12 days after USgHIFU treatment, in the retrospective case series of 27,053 patients including 17,402 patients with uterine fibroids. The patients were treated by surgery. ¹ Intestinal perforation was reported in less than 1% (2/9,988) of all patients with uterine fibroids or adenomyosis between 15 to 30 days of USgHIFU treatment in the retrospective case series of 9,988 patients.²

Gastrointestinal adverse event was reported in 21% (19/89) of patients after USgHIFU and in 49% (20/41) of patients after laparoscopic myomectomy in the prospective comparative study of 130 patients with symptomatic uterine fibroids having USgHIFU or laparoscopic myomectomy ($p < 0.001$).⁷ Intestinal complication was reported in less than 1% (3/9,988) of all patients with uterine fibroids or adenomyosis within 8 to 30 days of USgHIFU treatment in the retrospective case series of 9,988 patients.²

Deep vein thrombosis was reported in less than 1% of patients (2/17,402) with uterine fibroids after USgHIFU treatment, in the retrospective case series of 27,053 patients including 17,402 patients with uterine fibroids. ¹

Hydronephrosis was reported in 1 patient with uterine fibroids after USgHIFU treatment, in the retrospective case series of 27,053 patients including 17,402 patients with uterine fibroids. ¹

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Pubic symphysis injury was reported in 1 patient with uterine fibroids after USgHIFU treatment, in the retrospective case series of 27,053 patients including 17,402 patients with uterine fibroids.¹

Thrombocytopenia was reported in 1 patient with uterine fibroids after USgHIFU treatment, in the retrospective case series of 27,053 patients including 17,402 patients with uterine fibroids.¹

Blurred vision was reported in less than 1% (2/9,988) of all patients with uterine fibroids or adenomyosis within 7 days of USgHIFU treatment in the retrospective case series of 9,988 patients.² Blurred vision was reported in less than 1% (10/1,353) of patients after treatment in the USgHIFU group compared with none of the patients in the surgery group in the prospective non-randomised cohort study of 2,411 patients with fibroids having USgHIFU, myomectomy or hysterectomy.³

Hernia in the abdominal wall was reported in 1 patient out of 9,988 patients with uterine fibroids or adenomyosis more than 90 days after USgHIFU treatment in the retrospective case series of 9,988 patients.²

Respiratory tract infection was reported in less than 1% (1/1,353) of patients in the USgHIFU group compared with less than 1% (9/1,058) of patients in the surgery group in the prospective non-randomised cohort study of 2,411 patients with fibroids having USgHIFU, myomectomy or hysterectomy.³

Nausea and vomiting were reported in 2% (21/1,353) of patients in the USgHIFU group compared with 15% (158/1,058) of patients in the surgery group in the prospective non-randomised cohort study of 2,411 patients with fibroids having USgHIFU, myomectomy or hysterectomy.³

Dizziness and headache were reported in less than 1% (2/1,353) of patients in the USgHIFU group compared with less than 1% (1/1,058) of patients in the surgery group in the prospective non-randomised cohort study of 2,411 patients with fibroids having USgHIFU, myomectomy or hysterectomy.³

Neurological symptoms were reported in 15% (7/48) of patients who had USgHIFU compared with 4% (2/52) of patients who had myomectomy in the prospective RCT of 100 patients with symptomatic uterine fibroids ($p=0.083$).⁴ Nervous system adverse event was reported in 4% (4/89) of patients after USgHIFU and in 15% (6/41) of patients after laparoscopic myomectomy in the prospective comparative study of 130 patients with symptomatic uterine fibroids having USgHIFU or laparoscopic myomectomy ($p=0.02$).⁷

Cardiovascular system adverse event was reported in 4% (4/89) of patients after USgHIFU and in 7% (3/41) of patients after laparoscopic myomectomy in

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

the prospective comparative study of 130 patients with symptomatic uterine fibroids having USgHIFU or laparoscopic myomectomy (no statistically significant difference between groups).⁷

Anecdotal and theoretical adverse events

In addition to safety outcomes reported in the literature, specialist advisers are asked about anecdotal adverse events (events which they have heard about) and about theoretical adverse events (events which they think might possibly occur, even if they have never happened). For this procedure, specialist advisers did not list any anecdotal or theoretical adverse events.

The evidence assessed

Rapid review of literature

The medical literature was searched to identify studies and reviews relevant to ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids. The following databases were searched, covering the period from their start to 18 October 2018: MEDLINE, PREMEDLINE, EMBASE, Cochrane Library and other databases. Trial registries and the Internet were also searched. No language restriction was applied to the searches (see the [literature search strategy](#)). Relevant published studies identified during consultation or resolution that are published after this date may also be considered for inclusion.

The following selection criteria (table 1) were applied to the abstracts identified by the literature search. Where selection criteria could not be determined from the abstracts the full paper was retrieved.

Table 1 Inclusion criteria for identification of relevant studies

Characteristic	Criteria
Publication type	Clinical studies were included. Emphasis was placed on identifying good quality studies. Abstracts were excluded where no clinical outcomes were reported, or where the paper was a review, editorial, or a laboratory or animal study. Conference abstracts were also excluded because of the difficulty of appraising study methodology, unless they reported specific adverse events that were not available in the published literature.
Patient	Patients with symptomatic uterine fibroids.
Intervention/test	Ultrasound-guided high-intensity transcutaneous focused ultrasound.
Outcome	Articles were retrieved if the abstract contained information relevant to the safety and/or efficacy.
Language	Non-English-language articles were excluded unless they were thought to add substantively to the English-language evidence base.

List of studies included in the IP overview

This IP overview is based on 28,209 patients from 1 RCT⁴, 4 non-randomised comparative studies^{3,5,7-8}, 3 case series^{1,2,6} and 1 case reports⁹.

Other studies that were considered to be relevant to the procedure but were not included in the main extraction table (table 2) are listed in the [appendix](#).

Table 2 Summary of key efficacy and safety findings on ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Study 1 Liu Y (2018)

Details

Study type	Retrospective case series
Country	China (19 centres)
Recruitment period	2011-17
Study population and number	n= 27,053 (17,402 with uterine fibroids) patients with benign uterine disease
Age and sex	Median 42 years; 100% female Median BMI: 22.5 kg/cm ²
Patient selection criteria	<u>Inclusion criteria</u> : confirmed diagnosis, patients agreed to have pre-HIFU and post-HIFU MRI evaluation, patients could communicate with physicians during the procedure of HIFU treatment. <u>Exclusion criteria</u> : the lesion could not be visualised, pregnancy or lactation, suspected or confirmed uterine malignant diseases.
Technique	All patients needed to have bowel preparation before HIFU treatment. On the morning of the treatment day, the skin from the umbilicus level to the upper margin of the pubic symphysis was shaved, degreased and degassed before HIFU. JC or JC200 models of focused ultrasound tumour therapeutic system (Chongqing Haifu Medical Technology, Co., Ltd) were used. Real-time monitoring was done using My-Lab70 type B ultrasonic equipment (Esaote Group).
Follow-up	1 month
Conflict of interest/source of funding	Lian Zhang is a senior consultant to Chongqing Haifu. This work was partially supported by the National Basic Research Programme of China, the National Natural Science Fund by the National Science Foundation of China and the National Key Technology R&D Program.

Analysis

Study design issues: The severity of adverse effects was evaluated according to the SIR classification system for complications by outcome: (1) Class A: no therapy, no consequence; (2) Class B: nominal therapy, no consequence; (3) Class C: require therapy, minor hospitalization (<48 h); (4) Class D: required major therapy, unplanned increase in level of care, prolonged hospitalisation (>48 h); (5) Class E: permanent adverse sequelae; (6) Class F: death.

Study population issues: Among the 27,053 patients, 17,402 had uterine fibroids, 8434 had adenomyosis, 876 had caesarean scar pregnancy, and 341 had placenta accreta. In the patients with uterine fibroids, 12,342 had a solitary fibroid and 5060 had multiple fibroids.

Key efficacy and safety findings

Efficacy	Safety																																																																																																												
Number of patients analysed: 27,053 (17,402 with uterine fibroids) NPV ratio (for patients with uterine fibroids; median [interquartile range]): 85% (75% to 94%)	SIR classification of adverse effects after USgHIFU treatment in <u>all patients</u> (n=27,053)																																																																																																												
	<table border="1"> <thead> <tr> <th>SIR classification</th> <th>Adverse effects</th> <th>Number of events</th> <th>Incidence rate (%)</th> </tr> </thead> <tbody> <tr> <td rowspan="9">Class A</td> <td>Mild lower abdominal pain</td> <td>8,263</td> <td>30%</td> </tr> <tr> <td>Sacrococcygeal pain</td> <td>2,833</td> <td>10%</td> </tr> <tr> <td>Abnormal vaginal discharge</td> <td>1,270</td> <td>5%</td> </tr> <tr> <td>Lower limb paraesthesia</td> <td>188</td> <td><1%</td> </tr> <tr> <td>Nausea and vomiting</td> <td>108</td> <td><1%</td> </tr> <tr> <td>Erythema on skin</td> <td>86</td> <td><1%</td> </tr> <tr> <td>Fever</td> <td>79</td> <td><1%</td> </tr> <tr> <td>Haematuria</td> <td>24</td> <td><1%</td> </tr> <tr> <td>Total</td> <td>12,851</td> <td>48%</td> </tr> <tr> <td rowspan="7">Class B</td> <td>Lower abdominal pain</td> <td>113</td> <td><1%</td> </tr> <tr> <td>Sacrococcygeal pain</td> <td>33</td> <td><1%</td> </tr> <tr> <td>Abnormal vaginal discharge</td> <td>27</td> <td><1%</td> </tr> <tr> <td>Skin blisters</td> <td>20</td> <td><1%</td> </tr> <tr> <td>Lower limb paresthesia</td> <td>19</td> <td><1%</td> </tr> <tr> <td>Fever</td> <td>3</td> <td><1%</td> </tr> <tr> <td>Total</td> <td>215</td> <td><1%</td> </tr> <tr> <td rowspan="9">Class C</td> <td>Skin burns</td> <td>38</td> <td><1%</td> </tr> <tr> <td>Leg pain</td> <td>17</td> <td><1%</td> </tr> <tr> <td>Vaginal discharge or bleeding</td> <td>13</td> <td><1%</td> </tr> <tr> <td>Urinary retention</td> <td>8</td> <td><1%</td> </tr> <tr> <td>Hyperpyrexia</td> <td>7</td> <td><1%</td> </tr> <tr> <td>Acute cystitis</td> <td>4</td> <td><1%</td> </tr> <tr> <td>Intrauterine infection</td> <td>3</td> <td><1%</td> </tr> <tr> <td>Total</td> <td>90</td> <td><1%</td> </tr> <tr> <td rowspan="8">Class D</td> <td>Bowel injury</td> <td>4</td> <td><1%</td> </tr> <tr> <td>Acute renal failure</td> <td>4</td> <td><1%</td> </tr> <tr> <td>Deep vein thrombosis</td> <td>2</td> <td><1%</td> </tr> <tr> <td>Pubic symphysis injury</td> <td>1</td> <td><1%</td> </tr> <tr> <td>Post-HIFU thrombocytopenia</td> <td>1</td> <td><1%</td> </tr> <tr> <td>Sciatic nerve injury</td> <td>1</td> <td><1%</td> </tr> <tr> <td>Hydronephrosis</td> <td>1</td> <td><1%</td> </tr> <tr> <td>Total</td> <td>14</td> <td><1%</td> </tr> <tr> <td>Class E and F</td> <td></td> <td>0</td> <td>0%</td> </tr> </tbody> </table>	SIR classification	Adverse effects	Number of events	Incidence rate (%)	Class A	Mild lower abdominal pain	8,263	30%	Sacrococcygeal pain	2,833	10%	Abnormal vaginal discharge	1,270	5%	Lower limb paraesthesia	188	<1%	Nausea and vomiting	108	<1%	Erythema on skin	86	<1%	Fever	79	<1%	Haematuria	24	<1%	Total	12,851	48%	Class B	Lower abdominal pain	113	<1%	Sacrococcygeal pain	33	<1%	Abnormal vaginal discharge	27	<1%	Skin blisters	20	<1%	Lower limb paresthesia	19	<1%	Fever	3	<1%	Total	215	<1%	Class C	Skin burns	38	<1%	Leg pain	17	<1%	Vaginal discharge or bleeding	13	<1%	Urinary retention	8	<1%	Hyperpyrexia	7	<1%	Acute cystitis	4	<1%	Intrauterine infection	3	<1%	Total	90	<1%	Class D	Bowel injury	4	<1%	Acute renal failure	4	<1%	Deep vein thrombosis	2	<1%	Pubic symphysis injury	1	<1%	Post-HIFU thrombocytopenia	1	<1%	Sciatic nerve injury	1	<1%	Hydronephrosis	1	<1%	Total	14	<1%	Class E and F		0	0%
	SIR classification	Adverse effects	Number of events	Incidence rate (%)																																																																																																									
	Class A	Mild lower abdominal pain	8,263	30%																																																																																																									
		Sacrococcygeal pain	2,833	10%																																																																																																									
		Abnormal vaginal discharge	1,270	5%																																																																																																									
		Lower limb paraesthesia	188	<1%																																																																																																									
		Nausea and vomiting	108	<1%																																																																																																									
		Erythema on skin	86	<1%																																																																																																									
		Fever	79	<1%																																																																																																									
		Haematuria	24	<1%																																																																																																									
		Total	12,851	48%																																																																																																									
	Class B	Lower abdominal pain	113	<1%																																																																																																									
		Sacrococcygeal pain	33	<1%																																																																																																									
		Abnormal vaginal discharge	27	<1%																																																																																																									
		Skin blisters	20	<1%																																																																																																									
		Lower limb paresthesia	19	<1%																																																																																																									
		Fever	3	<1%																																																																																																									
		Total	215	<1%																																																																																																									
	Class C	Skin burns	38	<1%																																																																																																									
		Leg pain	17	<1%																																																																																																									
		Vaginal discharge or bleeding	13	<1%																																																																																																									
		Urinary retention	8	<1%																																																																																																									
		Hyperpyrexia	7	<1%																																																																																																									
		Acute cystitis	4	<1%																																																																																																									
		Intrauterine infection	3	<1%																																																																																																									
		Total	90	<1%																																																																																																									
Class D		Bowel injury	4	<1%																																																																																																									
	Acute renal failure	4	<1%																																																																																																										
	Deep vein thrombosis	2	<1%																																																																																																										
	Pubic symphysis injury	1	<1%																																																																																																										
	Post-HIFU thrombocytopenia	1	<1%																																																																																																										
	Sciatic nerve injury	1	<1%																																																																																																										
	Hydronephrosis	1	<1%																																																																																																										
	Total	14	<1%																																																																																																										
Class E and F		0	0%																																																																																																										

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Incidence of major complications (class C and D of the SIR classification) after USgHIFU treatment in patients with uterine fibroids

Complications	Incidence % (number of patients) n=17,402
Skin burns	0.1494 (26)
Leg pain	0.0575 (10)
Urinary retention	0.0402 (7)
Vaginal bleeding	0.0345 (6)
Hyperpyrexia	0.0287 (5)
Renal failure	0.0230 (4)
Acute cystitis	0.0172 (3)
Bowel injury*	0.0172 (3)
Intrauterine infection	0.0115 (2)
Deep vein thrombosis	0.0115 (2)
Hydronephrosis	0.0057 (1)
Pubic symphysis injury	0.0057 (1)
Thrombocytopenia	0.0057 (1)
TOTAL	0.4080

The incidence rates of the major complications among patients with uterine fibroids, adenomyosis and placenta accrete were not statistically significantly different.

*This occurred between 4 and 12 days after the procedure and the patients were treated by surgery.

Abbreviations used: BMI, body mass index; HIFU, high-intensity focused ultrasound; NPV, non-perfused volume; SIR, society of interventional radiology; USgHIFU, ultrasound-guided HIFU.

Study 2 Chen J (2015)

Details

Study type	Retrospective case series
Country	China (16 centres)
Recruitment period	2006-07
Study population and number	n= 9,988 patients with uterine fibroids (7,438) or adenomyosis (2,549)
Age and sex	Mean 40 years; 100% female
Patient selection criteria	<p>Inclusion criteria: age>18, no pregnancy desire in the near future; clinically diagnosed with uterine fibroids or adenomyosis with symptoms like dysmenorrhea and menorrhagia; uterine fibroids or adenomyosis confirmed by enhanced MRI examinations; clear imaging of the lesion by ultrasound monitor built in the HIFU treatment system, and ultrasound focal point able to be located inside the lesions with its focal region covering most of the lesion; no bone or cannot move gas-containing organ found in the ultrasonic path; no allergy to contrast agent or contraindication for MRI examination; free from cognitive impairment, and able to communicate therapeutic experience with the medical staff; consent to ultrasound ablation therapy and having signed the informed consent form; consent to the use of their clinical data and imaging data for medical study and publication.</p> <p>Exclusion criteria: patients with scars in their lower abdomen that could cause obvious sound attenuation or having a history of radiation therapy; suspected of or confirmed as uterine malignancy; acute infectious pelvic disorders.</p>
Technique	<p>The ultrasound ablation procedure was done with an USgHIFU tumour therapeutic system [JC or JC200, Chongqing Haifu (HIFU) Tech Co., Ltd]. The device features the built-in B-mode ultrasound (Esaote MyLab70) that provides real-time visualisation during the treatment.</p> <p>Prophylactic antibiotics were prescribed orally for 3 days.</p>
Follow-up	Minimum 6 months
Conflict of interest/source of funding	Wen-Zhi Chen is a shareholder and a consultant for Chongqing Haifu Medical Technologies Inc. Lian Zhang and Ke-Quan Li are consultants to Chongqing Haifu Medical Technologies Inc. Other authors have no conflicts of interest. The study was supported by the National Key Technology Research and Development Program.

Analysis

Study design issues:

- 42 doctors did the procedure.
- The severity of adverse effects was evaluated according to the SIR classification system for complications by outcome: (1) Class A: no therapy, no consequence; (2) Class B: nominal therapy, no consequence; (3) Class C: require therapy, minor hospitalization (<48 h); (4) Class D: required major therapy, unplanned increase in level of care, prolonged hospitalisation (>48 h); (5) Class E: permanent adverse sequelae; (6) Class F: death.

Study population issues:

- 6,545 patients had a solitary uterine fibroid, 818 had multiple uterine fibroids, and 76 had fibroids complicated with adenomyosis.
- There were mainly 3 types of fibroids: submucous myoma in 89 patients (12%), intramural myoma in 5,059 patients (68%) and subserosal myoma in 1,478 patients (20%).
- Fibroids location: 3,496 fibroids were found in the anterior wall (47%), 2,306 in the posterior wall (31%), 447 in the lateral wall (6%), and 1,190 in fundus (16.0%).
- The median volume of the dominant fibroid tumour was 67.5 cm³ (interquartile range, 38.1 to 134.5 cm³).

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Key efficacy and safety findings

Efficacy	Safety																																																																																																																												
<p>Number of patients analysed: 9,988 patients with uterine fibroids (7,438) or adenomyosis (2,549)</p> <p>For uterine fibroids only</p> <p>Technical success rate (NPV ratio over 25% of the tumour volume): 98% (7,319/7,439)</p> <p>Volume of ablation (median [1/4, 3/4]): 78.5 cm³ (53.1, 129.4)</p> <p>NPV rate (%; mean): 83.1 ± 15.6 (range 25.0 to 100.0)</p>	<p>Adverse reactions after HIFU (all patients, N=9,988)</p> <table border="1"> <thead> <tr> <th>Description</th> <th>% patients (n)</th> <th>1-7 days</th> <th>8-14 days</th> <th>15-30 days</th> <th>31-90 days</th> <th>>90 days</th> </tr> </thead> <tbody> <tr> <td>Vaginal secretion</td> <td>9% (874)</td> <td>768</td> <td>106</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Lower abdominal pain</td> <td>2% (225)</td> <td>225</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Leg or buttock pain</td> <td><1% (76)</td> <td>55</td> <td>12</td> <td>7</td> <td>2</td> <td>0</td> </tr> <tr> <td>Odynuria or haematuria</td> <td><1% (52)</td> <td>52</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Uterus bleeding</td> <td><1% (24)</td> <td>20</td> <td>4</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Blurred vision</td> <td><1% (2)</td> <td>2</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Skin burns</td> <td><1% (26)</td> <td>22</td> <td>4</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Urinary retention</td> <td><1% (16)</td> <td>16</td> <td>0</td> <td>0</td> <td></td> <td>0</td> </tr> <tr> <td>Fever</td> <td><1% (4)</td> <td>4</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Intestinal</td> <td><1% (3)</td> <td>0</td> <td>2</td> <td>1</td> <td>0</td> <td>0</td> </tr> <tr> <td>Intestinal perforation</td> <td><1% (2)</td> <td>0</td> <td>0</td> <td>2</td> <td>0</td> <td>0</td> </tr> <tr> <td>Hernia in abdominal wall</td> <td><1% (1)</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> </tr> <tr> <td>Total</td> <td>1305</td> <td>89% (1164/1305)</td> <td>10% (128/1305)</td> <td><1% (10/1305)</td> <td><1% (2/1305)</td> <td><1% (1/1305)</td> </tr> </tbody> </table> <p>No permanent injury or fatal complication occurred.</p> <p>Adverse reactions according to SIR classification</p> <table border="1"> <thead> <tr> <th>SIR classification</th> <th>% of adverse reactions</th> <th>% of patients</th> </tr> </thead> <tbody> <tr> <td>Class A</td> <td>94% (1228/1305)</td> <td>12% (1228/9988)</td> </tr> <tr> <td>Class B</td> <td>3% (45/1305)</td> <td><1% (45/9988)</td> </tr> <tr> <td>Class C</td> <td>2% (24/1305)</td> <td><1% (26/9988)</td> </tr> <tr> <td>Class D</td> <td><1% (8/1305)</td> <td><1% (6/9988)</td> </tr> <tr> <td>Class E</td> <td>0</td> <td>0</td> </tr> <tr> <td>Class F</td> <td>0</td> <td>0</td> </tr> </tbody> </table>						Description	% patients (n)	1-7 days	8-14 days	15-30 days	31-90 days	>90 days	Vaginal secretion	9% (874)	768	106	0	0	0	Lower abdominal pain	2% (225)	225	0	0	0	0	Leg or buttock pain	<1% (76)	55	12	7	2	0	Odynuria or haematuria	<1% (52)	52	0	0	0	0	Uterus bleeding	<1% (24)	20	4	0	0	0	Blurred vision	<1% (2)	2	0	0	0	0	Skin burns	<1% (26)	22	4	0	0	0	Urinary retention	<1% (16)	16	0	0		0	Fever	<1% (4)	4	0	0	0	0	Intestinal	<1% (3)	0	2	1	0	0	Intestinal perforation	<1% (2)	0	0	2	0	0	Hernia in abdominal wall	<1% (1)	0	0	0	0	1	Total	1305	89% (1164/1305)	10% (128/1305)	<1% (10/1305)	<1% (2/1305)	<1% (1/1305)	SIR classification	% of adverse reactions	% of patients	Class A	94% (1228/1305)	12% (1228/9988)	Class B	3% (45/1305)	<1% (45/9988)	Class C	2% (24/1305)	<1% (26/9988)	Class D	<1% (8/1305)	<1% (6/9988)	Class E	0	0	Class F	0	0
Description	% patients (n)	1-7 days	8-14 days	15-30 days	31-90 days	>90 days																																																																																																																							
Vaginal secretion	9% (874)	768	106	0	0	0																																																																																																																							
Lower abdominal pain	2% (225)	225	0	0	0	0																																																																																																																							
Leg or buttock pain	<1% (76)	55	12	7	2	0																																																																																																																							
Odynuria or haematuria	<1% (52)	52	0	0	0	0																																																																																																																							
Uterus bleeding	<1% (24)	20	4	0	0	0																																																																																																																							
Blurred vision	<1% (2)	2	0	0	0	0																																																																																																																							
Skin burns	<1% (26)	22	4	0	0	0																																																																																																																							
Urinary retention	<1% (16)	16	0	0		0																																																																																																																							
Fever	<1% (4)	4	0	0	0	0																																																																																																																							
Intestinal	<1% (3)	0	2	1	0	0																																																																																																																							
Intestinal perforation	<1% (2)	0	0	2	0	0																																																																																																																							
Hernia in abdominal wall	<1% (1)	0	0	0	0	1																																																																																																																							
Total	1305	89% (1164/1305)	10% (128/1305)	<1% (10/1305)	<1% (2/1305)	<1% (1/1305)																																																																																																																							
SIR classification	% of adverse reactions	% of patients																																																																																																																											
Class A	94% (1228/1305)	12% (1228/9988)																																																																																																																											
Class B	3% (45/1305)	<1% (45/9988)																																																																																																																											
Class C	2% (24/1305)	<1% (26/9988)																																																																																																																											
Class D	<1% (8/1305)	<1% (6/9988)																																																																																																																											
Class E	0	0																																																																																																																											
Class F	0	0																																																																																																																											
<p>Abbreviations used: HIFU, high-intensity focused ultrasound; NPV, non-perfused volume; SIR, society of interventional radiology; USgHIFU, ultrasound-guided HIFU.</p>																																																																																																																													

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Study 3 Chen J (2017)

Details

Study type	Prospective non-randomised cohort study
Country	China (20 centres)
Recruitment period	2011-13
Study population and number	n= 2,411 (1,353 USgHIFU versus 586 myomectomy versus 472 hysterectomy) women with symptomatic fibroids
Age and sex	USgHIFU: Mean 41 years; mean BMI: 23 Hysterectomy: Mean 47 years; mean BMI: 24 Myomectomy: Mean 41 years; mean BMI: 23
Patient selection criteria	<u>Inclusion criteria</u> : Premenopausal women who had completed their planned family (and had no recent plan for a further pregnancy). Imaging-confirmed diagnosis of symptomatic fibroids with any of the following indications for hysterectomy: (a) enlarged uterus; (b) menorrhagia or secondary anaemia; (c) pelvic pain, urinary frequency, or constipation. For patients with multiple fibroids, no more than 3 fibroids with minimal diameters of 2 cm based on abdominal ultrasound present. Fibroids clearly imaged by abdominal ultrasound. For patients with abdominal surgical scars, the width of image blurring because of acoustic attenuation had to be <10 mm. <u>Exclusion criteria</u> : Patients with uterine adenomyosis. Previous myomectomy. Concurrent pregnancy. Pedunculated subserous or submucosal fibroids. Any single fibroid >10 cm maximum diameter. Acute pelvic inflammation or uncontrolled systemic disease. Patients unable to communicate adequately with physicians, or unwilling to sign informed consent.
Technique	<u>USgHIFU</u> : A single session of HIFU ablation was done using the JC (JC200) Focused Ultrasound Therapeutic Unit for Tumour (Chongqing Haifu Medical Technology Co., Ltd). Treatment was monitored by real-time ultrasonography. After the procedure, patients lay prone for 2 hours under observation. <u>Surgical procedures</u> : The surgical route of hysterectomy or myomectomy was left to the discretion of the attending gynaecologist.
Follow-up	1 year
Conflict of interest/source of funding	No conflict of interest declared. This project was funded by the National Key Technology R&D Program.

Analysis

Follow-up issues:

- Follow-up visits were scheduled at 6 months and 12 months post-procedure.
- At 12-month follow-up, the rate of patients lost to follow-up were 7% (89/1,353) in the USgHIFU group, 5% (32/586) in the myomectomy group and 3% (13/472) in the hysterectomy group.

Study design issues:

- The main objective of the study was to evaluate the clinical outcomes of USgHIFU and surgery in treating uterine fibroids, and prepare for a randomised trial.
- Patients were given written information describing the potential risks and benefits associated with each procedure, including the likely effects on fertility and the risk of recurrence of symptom. Patients made the choices according to their preference after being informed of all 3 options.
- To adjust for the effects of inequalities between treatment groups, multiple regression modelling was done to identify the influence of preselected covariates on the dependent variable. This process was carried out for the total UFS and QoL scores.

Study population issues: The mean age of the USgHIFU group was lower than that of the surgery group (myomectomy plus hysterectomy). Other group differences included BMI, uterine volume and UFS score.

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Key efficacy and safety findings

Efficacy					Safety																																																					
Number of patients analysed: 2,411 (1,353 USgHIFU versus 586 myomectomy versus 472 hysterectomy)					Adverse events allocated to treatment																																																					
Mean NPV score for USgHIFU: 87%					Adverse event	HIFU group (n = 1353)	Surgery group (myomectomy or hysterectomy, n = 1058)	Myomectomy group (n = 586)																																																		
Re-intervention rate at 1 year (defined as any need for recurrent treatment of fibroid-related symptoms, assessed for the HIFU and myomectomy groups only): - USgHIFU group: 1% (14/1,353) - Myomectomy group: 0% (0/586) The re-interventions were: one second HIFU treatment, 12 myomectomies and 1 hysterectomy.					Minor adverse event	25% (335)	68% (719)	68% (397)																																																		
Pregnancy rate at 1 year: - USgHIFU group: 2% (28/1,353) - Myomectomy group: 0.7% (4/586) - Hysterectomy group: 0% (0/472)					Abdominal distension	0	<1% (4)	<1% (3)																																																		
UFS-QoL score (mean ± SD) - Both scales range from 0 to 100, but high scores indicate better QoL but more serious symptoms on the UFS scale					Lumbar and back (sacrum) pain	11% (150)	13% (134)	11% (64)																																																		
<table border="1"> <thead> <tr> <th rowspan="2">Parameter</th> <th colspan="4">UFS-QoL score or change in score</th> </tr> <tr> <th>HIFU group (n = 1353)</th> <th>Myomectomy group (n = 586)</th> <th>p (unadjusted)</th> <th>p (adjusted)</th> </tr> </thead> <tbody> <tr> <td colspan="5">UFS</td> </tr> <tr> <td>Baseline</td> <td>19.89 ± 14.29</td> <td>15.34 ± 13.34</td> <td>0.000</td> <td></td> </tr> <tr> <td>At 6 months</td> <td>10.20 ± 10.18</td> <td>7.09 ± 8.25</td> <td>0.000</td> <td></td> </tr> <tr> <td>At 12 months</td> <td>7.73 ± 9.65</td> <td>5.77 ± 7.77</td> <td>0.000</td> <td></td> </tr> <tr> <td>Absolute difference at 6 months</td> <td>-9.84 ± 13.37</td> <td>-8.23 ± 13.10</td> <td>0.002</td> <td>0.034</td> </tr> <tr> <td>Absolute difference at 12 months</td> <td>-12.17 ± 9.71</td> <td>-9.71 ± 13.69</td> <td>0.000</td> <td>0.001</td> </tr> <tr> <td colspan="5">QoL</td> </tr> <tr> <td>Baseline</td> <td>72.75 ± 16.33</td> <td>72.85 ± 14.46</td> <td>0.532</td> <td></td> </tr> </tbody> </table>					Parameter	UFS-QoL score or change in score				HIFU group (n = 1353)	Myomectomy group (n = 586)	p (unadjusted)	p (adjusted)	UFS					Baseline	19.89 ± 14.29	15.34 ± 13.34	0.000		At 6 months	10.20 ± 10.18	7.09 ± 8.25	0.000		At 12 months	7.73 ± 9.65	5.77 ± 7.77	0.000		Absolute difference at 6 months	-9.84 ± 13.37	-8.23 ± 13.10	0.002	0.034	Absolute difference at 12 months	-12.17 ± 9.71	-9.71 ± 13.69	0.000	0.001	QoL					Baseline	72.75 ± 16.33	72.85 ± 14.46	0.532		Shoulder and back pain	0	1% (11)	2% (11)	
Parameter	UFS-QoL score or change in score																																																									
	HIFU group (n = 1353)	Myomectomy group (n = 586)	p (unadjusted)	p (adjusted)																																																						
UFS																																																										
Baseline	19.89 ± 14.29	15.34 ± 13.34	0.000																																																							
At 6 months	10.20 ± 10.18	7.09 ± 8.25	0.000																																																							
At 12 months	7.73 ± 9.65	5.77 ± 7.77	0.000																																																							
Absolute difference at 6 months	-9.84 ± 13.37	-8.23 ± 13.10	0.002	0.034																																																						
Absolute difference at 12 months	-12.17 ± 9.71	-9.71 ± 13.69	0.000	0.001																																																						
QoL																																																										
Baseline	72.75 ± 16.33	72.85 ± 14.46	0.532																																																							
					Numbness and pain in lower limb	3% (34)	2% (18)	2% (11)																																																		
					Weakness in lower limb	<1% (9)	6% (62)	5% (30)																																																		
					Pain and distension of anus	<1% (11)	4% (38)	3% (18)																																																		
					Subcutaneous emphysema	0	<1% (5)	<1% (5)																																																		
					Uterine bleeding	7% (88)	21% (222)	26% (150)																																																		
					Urinary retention	<1% (2)	2% (25)	1% (7)																																																		
					Haematuria	<1% (3)	2% (18)	1% (7)																																																		
					Fever (no therapy)	<1% (2)	<1% (6)	<1% (3)																																																		
					Respiratory tract infection	<1% (1)	<1% (9)	<1% (4)																																																		
					Fat liquefaction of incision	0	<1% (4)	<1% (3)																																																		
					Incision infection	0	<1% (1)	0																																																		
					Skin burn (1st to 2nd degree)	<1% (2)	0	0																																																		
					Nausea and vomiting	2% (21)	15% (158)	14% (80)																																																		
					Dizziness and headache	<1% (2)	<1% (1)	0																																																		

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

At 6 months	82.49 ± 12.94	80.44 ± 12.41	0.000		Blood pressure unsteadiness	-	<1% (1)	-
At 12 months	85.84 ± 12.22	83.45 ± 11.28	0.000		Blurred vision	<1% (10)	0	0
Absolute difference at 6 months	9.61 ± 14.01	7.42 ± 12.83	0.001	0.001	Choking sensation in chest	0	<1% (1)	<1% (1)
Absolute difference at 12 months	12.89 ± 16.16	10.50 ± 15.33	0.008	0.002	Stomach pain	0	<1% (1)	-
<p>The UFS-QoL cannot be used appropriately after hysterectomy.</p> <p>Hospital length of stay (mean)</p> <ul style="list-style-type: none"> - USgHIFU group: 4 days - Myomectomy group: 9 days - Hysterectomy group: 10.5 days <p>p<0.001 for the comparison between USgHIFU and surgery.</p> <p>Time to return to work (mean)</p> <ul style="list-style-type: none"> - USgHIFU group: 4 days - Myomectomy group: 24 days - Hysterectomy group: 29.5 days <p>p<0.001 for the comparison between USgHIFU and surgery.</p>					Major adverse events	<1% (3)	13% (133)	10% (60)
					Intraoperative massive haemorrhage (≥ 400 ml)	0	1% (11)	1% (7)
					Intraoperative blood transfusion	0	9% (96)	7% (41)
					Fever (>38°C)	0	<1% (3)	<1% (2)
					Pelvic abdominal infection	0	<1% (5)	<1% (3)
					Incision infection	0	<1% (3)	<1% (1)
					Second-degree skin burn	<1% (3)	0	0
					Respiratory tract infection	0	<1% (2)	<1% (1)
					Readmission	0	<1% (3)	0
					Deep venous thrombosis (lower limbs)	0	<1% (2)	<1% (1)
					Vaginal cuff bleeding	0	<1% (1)	0
					Vaginal cuff infection	0	<1% (1)	0
					Drainage-site infection	0	<1% (1)	<1% (1)
					Pelvic haematoma (drainage)	0	<1% (1)	<1% (1)
					Pelvic abscess (drainage)	0	<1% (1)	<1% (1)
					Bladder injury	0	<1% (1)	0
					Abdominal distension and vomiting (indwelling gastric tube)	0	<1% (1)	0

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

	Arrhythmia (emergency)	0	<1% (1)	<1% (1)
Abbreviations used: BMI, body mass index; NPV, non-perfused volume; QoL, quality of life; SD, standard deviation; UFS, uterine fibroid symptoms score; USgHIFU, ultrasound-guided HIFU				

Study 4 Wang X (2013)

Details

Study type	Prospective RCT
Country	China (1 centre)
Recruitment period	2010-11
Study population and number	n= 100 (48 USgHIFU versus 52 myomectomy) premenopausal patients with symptomatic uterine fibroids
Age and sex	USgHIFU: Mean 39 years; 100% (48/48) female; mean BMI: 22 Myomectomy: Mean 38 years; 100% (52/52) female; mean BMI: 22
Patient selection criteria	<u>Inclusion criteria</u> : premenopausal; clinically diagnosed with symptomatic uterine fibroids (as confirmed by ultrasonography) and presenting with operation indications and no wish to conceive. <u>Exclusion criteria</u> : submucous fibroids or pedunculated subserous fibroids; presence of other gynecological disorders, including vaginitis, pelvic inflammation, ovarian tumour, endometriosis, cervical dysplasia or symptomatic prolapse; menstruating, pregnant or breastfeeding women; or abnormal liver or renal function. Patients with submucous fibroids or pedunculated subserous fibroids.
Technique	<u>USgHIFU</u> : patients were treated with JC-focused ultrasound cancer treatment system under the guidance of real-time ultrasound. All patients received the maximum power of 400 W, except 1 patient who received 415 W. <u>Myomectomy</u> : the same group of surgeons did the procedures. Endotracheal intubation and general anaesthesia were administered to all patients. All steps were done using conventional surgical techniques and instruments via an abdominal transverse incision.
Follow-up	6 months
Conflict of interest/source of funding	None. This study was supported by the Grants from the National Natural Science Foundation of China and the Scientific and Technological Project of Chongqing.

Analysis

Follow-up issues: 110 patients were first randomised to the USgHIFU or to the myomectomy group using a computer-generated sequence and each group included 55 patients. In the USgHIFU group, 2 patients withdrew their consent and 5 patients were lost to follow-up. In the Myomectomy group, 3 patients were lost to follow-up. The total proportion of patients lost to follow-up was 10 %.

Study design issues:

- The purpose of this study was to evaluate the changes in sexual life associated with USgHIFU treatment compared with surgical treatment. The brief index of sexual functioning (BISF-W) was used to evaluate changes in sexual function. Differences in the outcome were calculated for each individual before treatment and at 3 and 6 months after treatment, and changes were compared between groups.
- The BISF-W questionnaire has 22 questions in 7 dimensions investigating all aspects of sexual life. The possible range of total score is -16 to +75. Higher scores indicate a higher quality of sexual function, except for 1 dimension (problems affecting sexual function).
- The BISF-W was only completed by patients who had been sexually active in the 4 weeks before administration of the questionnaire.
- Power analysis of the difference of the dimension scores at follow-up indicated that all patients from each group were needed to detect a clinically relevant 20 % difference between the groups ($\alpha = 0.05$ and power $(1-\beta) = 0.8$).

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Key efficacy and safety findings

Efficacy				Safety																																																																			
Number of patients analysed: 100 (48 USgHIFU versus 52 myomectomy)				Adverse reactions and complications																																																																			
Operative results				<table border="1"> <thead> <tr> <th>Characteristic</th> <th>USgHIFU</th> <th>Myomectomy</th> <th>p values</th> </tr> </thead> <tbody> <tr> <td>Adverse reactions</td> <td>88% (42/48)</td> <td>79% (41/52)</td> <td>0.263^a</td> </tr> <tr> <td>Pain</td> <td>73% (35/48)</td> <td>54% (28/52)</td> <td>0.048^b</td> </tr> <tr> <td>Burning of skin</td> <td>25% (12/48)</td> <td>0</td> <td><0.001^a</td> </tr> <tr> <td>Vaginal bleeding/abnormal vaginal discharge</td> <td>6% (3/48)</td> <td>48% (25/52)</td> <td><0.001^a</td> </tr> <tr> <td>Irritation sign of bladder/urinary retention</td> <td>4% (2/48)</td> <td>21% (11/52)</td> <td>0.016^a</td> </tr> <tr> <td>Vomiting/abdominal distension</td> <td>0</td> <td>15% (8/52)</td> <td><0.001^a</td> </tr> <tr> <td>Neurological symptoms</td> <td>15% (7/48)</td> <td>4% (2/52)</td> <td>0.083^a</td> </tr> <tr> <td>Others</td> <td>8% (4/48)</td> <td>13% (7/52)</td> <td>0.529^a</td> </tr> <tr> <td>Complications</td> <td>0</td> <td>27% (14/52)</td> <td><0.001^a</td> </tr> <tr> <td>Postoperative complication</td> <td>0</td> <td>13% (7/52)</td> <td>0.013^a</td> </tr> <tr> <td>Transfusion</td> <td>0</td> <td>2% (1/52)</td> <td>>0.999^a</td> </tr> <tr> <td>Hospital readmission time (>24 h)</td> <td>0</td> <td>0</td> <td>-</td> </tr> <tr> <td>Anaesthesia-related complications</td> <td>0</td> <td>12% (6/52)</td> <td>0.027^a</td> </tr> <tr> <td>Severe complications</td> <td>0</td> <td>0</td> <td>-</td> </tr> <tr> <td>Death</td> <td>0</td> <td>0</td> <td>-</td> </tr> </tbody> </table>				Characteristic	USgHIFU	Myomectomy	p values	Adverse reactions	88% (42/48)	79% (41/52)	0.263 ^a	Pain	73% (35/48)	54% (28/52)	0.048^b	Burning of skin	25% (12/48)	0	<0.001^a	Vaginal bleeding/abnormal vaginal discharge	6% (3/48)	48% (25/52)	<0.001^a	Irritation sign of bladder/urinary retention	4% (2/48)	21% (11/52)	0.016^a	Vomiting/abdominal distension	0	15% (8/52)	<0.001^a	Neurological symptoms	15% (7/48)	4% (2/52)	0.083 ^a	Others	8% (4/48)	13% (7/52)	0.529 ^a	Complications	0	27% (14/52)	<0.001^a	Postoperative complication	0	13% (7/52)	0.013^a	Transfusion	0	2% (1/52)	>0.999 ^a	Hospital readmission time (>24 h)	0	0	-	Anaesthesia-related complications	0	12% (6/52)	0.027^a	Severe complications	0	0	-	Death	0	0	-
Characteristic	USgHIFU	Myomectomy	p values																																																																				
Adverse reactions	88% (42/48)	79% (41/52)	0.263 ^a																																																																				
Pain	73% (35/48)	54% (28/52)	0.048^b																																																																				
Burning of skin	25% (12/48)	0	<0.001^a																																																																				
Vaginal bleeding/abnormal vaginal discharge	6% (3/48)	48% (25/52)	<0.001^a																																																																				
Irritation sign of bladder/urinary retention	4% (2/48)	21% (11/52)	0.016^a																																																																				
Vomiting/abdominal distension	0	15% (8/52)	<0.001^a																																																																				
Neurological symptoms	15% (7/48)	4% (2/52)	0.083 ^a																																																																				
Others	8% (4/48)	13% (7/52)	0.529 ^a																																																																				
Complications	0	27% (14/52)	<0.001^a																																																																				
Postoperative complication	0	13% (7/52)	0.013^a																																																																				
Transfusion	0	2% (1/52)	>0.999 ^a																																																																				
Hospital readmission time (>24 h)	0	0	-																																																																				
Anaesthesia-related complications	0	12% (6/52)	0.027^a																																																																				
Severe complications	0	0	-																																																																				
Death	0	0	-																																																																				
<table border="1"> <thead> <tr> <th>Characteristic</th> <th>USgHIFU</th> <th>Myomectomy</th> <th>p values</th> </tr> </thead> <tbody> <tr> <td>Hospital stay, day</td> <td>1 (1, 2)</td> <td>4 (4, 6)</td> <td><0.001[*]</td> </tr> <tr> <td>Time of out-of-bed activity, hour</td> <td>1 (0.17, 5)</td> <td>48 (24, 72)</td> <td><0.001[*]</td> </tr> <tr> <td>Time to return to normal daily activities, day</td> <td>7 (2, 60)</td> <td>15 (7, 60)</td> <td><0.001[*]</td> </tr> </tbody> </table>				Characteristic	USgHIFU	Myomectomy	p values	Hospital stay, day	1 (1, 2)	4 (4, 6)	<0.001[*]	Time of out-of-bed activity, hour	1 (0.17, 5)	48 (24, 72)	<0.001[*]	Time to return to normal daily activities, day	7 (2, 60)	15 (7, 60)	<0.001[*]	<p>^a From Fisher's exact test</p> <p>^b From Pearson's Chi-squared test</p>																																																			
Characteristic	USgHIFU	Myomectomy	p values																																																																				
Hospital stay, day	1 (1, 2)	4 (4, 6)	<0.001[*]																																																																				
Time of out-of-bed activity, hour	1 (0.17, 5)	48 (24, 72)	<0.001[*]																																																																				
Time to return to normal daily activities, day	7 (2, 60)	15 (7, 60)	<0.001[*]																																																																				
<p>From the Mann–Whitney U test</p>																																																																							
Sexual activity (% of sexually active patients)																																																																							
<table border="1"> <thead> <tr> <th></th> <th>USgHIFU</th> <th>Myomectomy</th> <th>p values</th> </tr> </thead> <tbody> <tr> <td>Pre-operation</td> <td>100%</td> <td>100%</td> <td></td> </tr> <tr> <td>1 month</td> <td>81%</td> <td>17%</td> <td><0.001</td> </tr> <tr> <td>3 months</td> <td>100%</td> <td>96%</td> <td></td> </tr> <tr> <td>6 months</td> <td>100%</td> <td>100%</td> <td></td> </tr> </tbody> </table>					USgHIFU	Myomectomy	p values	Pre-operation	100%	100%		1 month	81%	17%	<0.001	3 months	100%	96%		6 months	100%	100%																																																	
	USgHIFU	Myomectomy	p values																																																																				
Pre-operation	100%	100%																																																																					
1 month	81%	17%	<0.001																																																																				
3 months	100%	96%																																																																					
6 months	100%	100%																																																																					
<p>Patients after myomectomy were advised not to have sexual activity during the month after surgery, while USgHIFU patients were advised to resume sexual activity depending on their physical condition without any special restraint.</p>																																																																							
BISF-W total scores compared with baseline at different time points (mean±SD)																																																																							
<table border="1"> <thead> <tr> <th>Total scores**</th> <th>USgHIFU</th> <th>Myomectomy</th> <th>p values</th> </tr> </thead> <tbody> <tr> <td>Pre-operation</td> <td>24.64 ± 6.64</td> <td>24.91 ± 6.51</td> <td>0.933</td> </tr> <tr> <td>3 months</td> <td>25.04 ± 4.54</td> <td>24.83 ± 4.99</td> <td>0.701</td> </tr> <tr> <td>6 months</td> <td>26.67 ± 5.15***</td> <td>26.82 ± 5.72***</td> <td>0.605</td> </tr> </tbody> </table>				Total scores**	USgHIFU	Myomectomy	p values	Pre-operation	24.64 ± 6.64	24.91 ± 6.51	0.933	3 months	25.04 ± 4.54	24.83 ± 4.99	0.701	6 months	26.67 ± 5.15***	26.82 ± 5.72***	0.605																																																				
Total scores**	USgHIFU	Myomectomy	p values																																																																				
Pre-operation	24.64 ± 6.64	24.91 ± 6.51	0.933																																																																				
3 months	25.04 ± 4.54	24.83 ± 4.99	0.701																																																																				
6 months	26.67 ± 5.15***	26.82 ± 5.72***	0.605																																																																				
<p>** A higher score represents more favorable sexual functioning</p> <p>***Statistically significant difference from baseline within group (p<0.05)</p>																																																																							
<p>Abbreviations used: BISF-W, brief index of sexual functioning; BMI, body mass index; HIFU, high-intensity focused ultrasound; SD, standard deviation; USgHIFU, ultrasound-guided HIFU</p>																																																																							

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Study 5 Zhang W (2016)

Details

Study type	Retrospective comparative study
Country	China
Recruitment period	2011-15
Study population and number	n= 442 (221 anteverted versus 221 retroverted uterus) women with a single uterine fibroid
Age and sex	Mean 42 years
Patient selection criteria	<u>Inclusion criteria</u> : patients were premenopausal and at least 18 years of age, patients agreed to have MRI examinations before and after USgHIFU treatment, patients had solitary uterine fibroids and the fibroids presented with hypointensity on T2WI of an MRI. <u>Exclusion criteria</u> : patients with uterine fibroids presenting as isointensity or hyperintensity on T2WI, patients with multiple fibroids, patients with suspected or confirmed malignant diseases.
Technique	USgHIFU ablation was performed using an ultrasound compatible HIFU tumour therapeutic system (JC200, Haifu VR Technology, Chongqing).
Follow-up	Immediately post-treatment
Conflict of interest/source of funding	None

Analysis

Follow-up issues: NPV of the fibroid (defined as the volume that was not enhanced in the contrast-enhanced MRI) was measured post-HIFU treatment.

Study design issues:

- The aim of the study was to compare the treatment outcomes of USgHIFU for uterine fibroids in patients with an anteverted uterus compared with a retroverted uterus.
- Two senior radiologists evaluated all MR images independently.

Study population issues: There were statistically significant differences between groups in the sonication power (lower for the retroverted uterus group) and in the total energy used (less energy used in the retroverted uterus group) ($p < 0.05$).

Key efficacy and safety findings

Efficacy				Safety			
Number of patients analysed: 442 (221 anteverted versus 221 retroverted uterus)				Incidence rates of adverse effects during the USgHIFU procedure			
Volume of fibroids (mean ± SD)				Variable	Anteverted uterus (n=221)	Retroverted uterus (n=221)	p
Variables	Anteverted uterus (n=221)	Retroverted uterus (n=221)	p	Transient leg pain	12%	14%	0.331
Post-HIFU lesion volume (cm³)	31.0 ± 38.1	29.1 ± 35.3	0.111	Sciatic/buttock pain	39%	72%	0
NPV (cm³)	27.1 ± 33.9	25.1 ± 33.1	0.212	Lower abdominal pain	69%	58%	0.012
NPV ratio (%)	87.7 ± 11.8	85.2 ± 18.7	0.00	Skin 'hot' sensation	48%	27%	0
				Groin pain	3%	13%	0
				Incidence rates of adverse effects and complications immediately after USgHIFU treatment.			
				Variable	Anteverted uterus (n=221)	Retroverted uterus (n=221)	p
				Fever	0%	0%	1
				Lower abdominal pain	17%	20%	0.312
				Sciatic/buttock pain	5%	14%	0.001
				Leg pain/numbness	0%	<1% (1/221)	0.5
				Vaginal discharge	5%	7%	0.214
				Skin burn	0%	2% (5/221)*	0.031
				*Resection was done in 2 patients.			
Abbreviations used: HIFU, high-intensity focused ultrasound, SD, standard deviation; T2WI, T2 weighted imaging, USgHIFU, ultrasound-guided HIFU							

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Study 6 Li J S (2017)

Details

Study type	Retrospective case series
Country	China (1 centre)
Recruitment period	2010-15
Study population and number	n= 189 nulliparous women with uterine fibroids who had USgHIFU treatment
Age and sex	Mean 31 years; 100% (189/189) female
Patient selection criteria	<u>Inclusion criteria</u> : aged 20–42 years, desire to maintain fertility, have normal sexual life without contraception after USgHIFU, women with uterine fibroids who never had a delivery history before USgHIFU. <u>Exclusion criteria</u> : underwent re-interventions including hysterectomy or bilateral oophorectomy after HIFU.
Technique	Treatment was administered using the Model JC Focused Ultrasound Tumour Therapeutic System (Chongqing Haifu Medical Technology Co. Ltd.) with the microwave emission output power set to 200–400 W under continuous real-time ultrasound guidance at 3.5 MHz. The effect of therapy was determined by color doppler ultrasound and contrast-enhanced ultrasound (SonoVue). After USgHIFU patients were told to use contraceptives for 3 months and abstain from sex until after 1 menstruation.
Follow-up	Median 3 years
Conflict of interest/source of funding	No competing interests declared. This study was supported by the National Basic Research Program of China, the National Natural Science Fund by the Chinese National Science Foundation and the National Instrumentation Program.

Analysis

Follow-up issues:

- All the patients were advised to return for ultrasound examination at 3 months, 6 months, and 12 months, and then once a year thereafter.
- All the nulliparous women were enrolled and called for follow up. An obstetrician and gynaecologist did the telephone interviews with patients and filled out the case follow-up form. Telephone follow-up information included menstruation, symptoms of uterine fibroids, sexual life, pregnancy, outcome of pregnancy, pregnancy process, and delivery information. The complications during pregnancy and delivery were acquired from the prenatal ultrasound examination report and medical discharge records.
- Loss to follow-up was determined when the doctor failed to reach the patient by telephone after more than 3 attempts over the course of several days. We noted the number of patients who successfully completed telephone follow-up and those patients who were lost to follow-up.

Study design issues:

- The main objective of the study was to evaluate the impact of USgHIFU treatment for uterine fibroids on pregnancy and pregnancy outcomes in women.
- During the study period, 1,232 women had USgHIFU treatment for uterine fibroids. Of these women, 311 patients met the inclusion criteria and follow-up data was obtained for 255 women. 66 women were excluded from the analysis because of no sexual life, use of contraception or hysterectomy.

Study population issues: Twenty women (11%) were more than 35 years old. Of the 189 women, 131 (69%) had a single fibroid and 58 (31%) had multiple fibroids when they were treated with USgHIFU.

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Key efficacy and safety findings

Efficacy	
Number of patients analysed: 189	
Symptom remission rate and fibroid volume	
Variables	Value
Clinical symptoms before USgHIFU (n, %)*	84% (159/189)
Symptoms remission after USgHIFU (n, %)*	89% (141/189)
Volume before HIFU (cm ³ , mean±SD) †	81.2 ± 80.6
Volume after HIFU (cm ³ , mean±SD) †	34.2 ± 48.3
Volume shrinkage (% , mean±SD)†	58.0 ± 31.3
*Whether clinical symptoms were relieved according to the patient's subjective evaluation.	
†In cases of multiple myomas, these findings refer to only the largest myoma.	
Pregnancy after USgHIFU	
Variables	Value
Pregnancy rate	69% (131/189)
Mean interval between USgHIFU treatment and pregnancy	12.3 ± 9.9 months
Spontaneous pregnancy rate	95% (125/131)
Pregnancy rate through assisted reproductive technology	5% (6/131)
Pregnancy rate of women with a history of infertility	20% (9/45)
Pregnancy outcomes after USgHIFU (n = 133)	
Pregnancy outcomes	Cases (n)
Delivery mode	70% (93/133)
Caesarean section*	72% (67/93)
Vaginal delivery	28% (26/93)
On-going pregnancy	14% (19/133)
Abortion	16% (21/133)
Spontaneous abortion	13% (17/133)
Induced abortion	3% (4/133)
Pregnancy complications	11% (10/93)
Labour complications	8% (7/93)
*Including 6 cases (4.5%) termination pregnancy in premature for obstetric factors.	
Neonates characteristics (n = 94)	
Variables	Value
Male/female (n)	49/45
Number of pregnancy (n)	93
Single pregnancy (n)	99% (92/93)
Twin pregnancy (n)	1% (1/93)
Pregnancy length (weeks)	37.5 ± 1.0
Birth weight (Kg)	3.3 ± 0.4
Low birth weight infants	4
Full term deliveries	94% (88/94)

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Preterm deliveries	6% (6/94)		
Characteristics between pregnancy group and non-pregnancy group			
Variables	Pregnancy group	Non-pregnancy group	p values
Cases (n)	131	68	-
Age (years)	30.3 ± 4.0	33.8 ± 4.2	0.000
Infertility history (n, %)	7% (9/131)	62% (36/58)	0.000
Number of myomas ablated (n)	1.2 ± 0.8	1.6 ± 1.0	0.008
Clinical symptoms before HIFU (n, %)*	84% (110/131)	84% (49/58)	0.874
Symptoms remission after HIFU (n, %)*	98% (108/110)	67% (33/49)	0.000
Volume shrinkage (%)†	60.0 ± 30.8	52.3 ± 32.7	0.094
*Whether clinical symptoms were relieved according to patient's subjective evaluation.			
†In cases of multiple myomas, these findings refer to only the largest myoma.			
Multivariate regression analysis was performed for the comparisons that were found to be statistically significant. Multivariate analysis indicated that age and a history of infertility were the factors that statistically significantly affected pregnancy after treatment ($p < 0.01$).			
Abbreviations used: HIFU, high-intensity focused ultrasound; SD, standard deviation; USgHIFU, ultrasound-guided HIFU			

Study 7 Wang F (2014)

Details

Study type	Non-randomised prospective comparative study
Country	China (single centre)
Recruitment period	2010-11
Study population and number	n= 130 (89 USgHIFU versus 41 laparoscopic myomectomy) women with symptomatic uterine myomas
Age and sex	Mean 38 years Mean BMI: 22
Patient selection criteria	<u>Inclusion criteria</u> : premenopausal status; age \geq 18 years; and presence of symptomatic uterine myomas, with no more than 3 myomas located intramurally or subserosally and the largest myoma <10 cm in diameter. <u>Exclusion criteria</u> : presence of asymptomatic uterine myomas, submucous or pedunculated myomas, pregnancy, contraindication for MRI or gadolinium injection solution, suspected or confirmed malignant uterine tumour, pelvic acute inflammatory disease, and systemic disease. In the USgHIFU group, patients were excluded if they had type 3 uterine myomas identified on the signal intensity of T2-weighted images.
Technique	For the USgHIFU procedure, the USgHIFU tumour therapeutic system (model JC HIFU; Chongqing Haifu Technology Co., Ltd) and B-mode ultrasound (MyLab70; Esaote SpA) were used. In the surgical group, laparoscopic myomectomy was done according to the method of Mais et al. If technical difficulty occurred and the surgery could not be finished using laparoscopy, the procedure was converted to conventional laparotomy. All surgical procedures were done by the same 2 experienced gynaecologists.
Follow-up	1 year
Conflict of interest/source of funding	The study was supported by a grant from the Health Ministry of Chongqing, China.

Analysis

Follow-up issues: In the HIFU group, 89 women were enrolled and treated, and 83 completed the 2 follow-up visits. In the surgical group, 41 were allocated to have laparoscopic myomectomy. Two procedures were converted to laparotomic myomectomy because of serious pelvic adhesions and 2 patients were lost to follow-up.

Study design issues:

- The main objective was to assess the quality of life of women at 1 and 12 months after USgHIFU treatment as compared with laparoscopic myomectomy for treatment of symptomatic uterine myomas.
- Patients were assigned to either the HIFU or the surgical group according to their preference.

Study population issues: The only significant difference in baseline characteristics between groups was that the largest mean myoma diameter in the HIFU group was 6.0 cm compared with 6.9 cm in the surgical group (p=0.02).

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Key efficacy and safety findings

Efficacy				Safety			
Number of patients analysed: 130 (89 USgHIFU versus 41 laparoscopic myomectomy)				Significant clinical complications and adverse events			
SF-36 score (mean [SD]) at admission and at 1 and 12 months after treatment. Scores range from 0 to 100 and higher scores indicate better function.							
Variable	USgHIFU Group	Surgical Group	p Value	Variable	USgHIFU Group (n=89)	Surgical Group (n=41)	p Value
At admission	n=89	n=41	-	Significant clinical complications			
Physical function	74.8 (24.9)	77.6 (23.8)	NS	Total number	19% (17)	27% (11)	NS
Physical role	46.5 (42.4)	49.2 (41.3)	NS	Skin burn	13% (12)	0	<0.001
Bodily pain	53.4 (23.9)	51.3 (29.5)	NS	Temperature >38°C on any 2 post-treatment days	2% (2)	10% (4)	NS
General health	64.8 (20.8)	69.5 (18.9)	NS	Transfusion	0	2% (1)	NS
Vitality	43.1 (24.1)	40.3 (24.5)	NS	Unintended surgical procedures related to treatment	0	5% (2)	NS
Social function	66.1 (29.4)	62.5 (28.3)	NS	Rehospitalisation within >24 hour	3% (3)	2% (1)	NS
Emotional role	64.4 (40.9)	65.4 (43.6)	NS	Anaesthesia related complication	0	7% (3)	0.006
Mental health	66.4 (19.1)	61.2 (22.4)	NS	Life-threatening event	0	0	NS
At 1 month	n=88	n=41	-	Death	0	0	NS
Physical function	88.4 (25.4) (p<0.001)	86.9 (24.7) (NS)	NS	Total significant clinical complications except skin burn	6% (5)	27% (11)	<0.001
Physical role	51.9 (33.4) (NS)	44.5 (29.6) (NS)	NS	Adverse events			
Bodily pain	53.9 (26.6) (NS)	55.7 (27.3) (NS)	NS	Pain/ discomfort	45% (40)	41% (17)	NS
General health	62.9 (20.8) (NS)	64.4 (19.9) (NS)	NS	Genital tract	28% (25)	22% (9)	NS
Vitality	48.7 (26.4) (NS)	49.0 (25.4) (NS)	NS	Irregular vaginal bleeding/ discharge	18% (16)	15% (6)	NS
Social function	61.4 (28.8) (NS)	63.5 (22.8) (NS)	NS	Infection	12% (11)	12% (5)	NS
Emotional role	52.4 (44.0) (NS)	70.3 (35.5) (NS)	0.02	Urinary tract	22% (20)	22% (9)	NS
Mental health	66.4 (18.0) (NS)	77.4 (19.4) (p<0.001)	0.002	Gastrointestinal tract	21% (19)	49% (20)	<0.001
At 12 months	n=83	n=39		Nervous system	4% (4)	15% (6)	0.02
Physical function	91.2 (20.4) (p<0.001)	89.9 (22.8) (p=0.02)	NS	Cardiovascular system	4% (4)	7% (3)	NS
Physical role	73.9 (33.4) (p<0.001)	72.5 (39.8) (p=0.01)	NS	Respiratory tract	0	2% (1)	NS
Bodily pain	75.3 (25.8) (p<0.001)	79.0 (27.3) (p<0.001)	NS	Other	2% (2)	5% (2)	NS

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

General health	74.9 (20.3) (p<0.001)	76.8 (21.9) (NS)	NS
Vitality	65.6 (25.5) (p<0.001)	64.9 (20.8) (p<0.001)	NS
Social function	85.7 (25.2) (p<0.001)	83.3 (26.3) (p<0.001)	NS
Emotional role	82.5 (35.4) (p<0.001)	80.9 (32.4) (NS)	NS
Mental health	80.4 (19.1) (p<0.001)	79.0 (23.4) (p<0.001)	NS

p values in parentheses denote comparison of SF-36 scores at admission versus at 1 or 12 months after treatment.

Effect of treatment on symptoms, willingness to recommend the treatment, hospital stay, and disability assessment (mean [SD])

Variable	USgHIFU Group	Surgical Group	p Value
Symptom score at 1 month*	3.3 (1.8) (n=89)	3.1 (2.2) (n=41)	NS
Symptom score at 12 months*	4.0 (2.3) (n=83)	4.3 (2.4) (n=39)	NS
Willingness to recommend treatment to a friend	89% (74/83)	92% (36/39)	NS
Hospital stay (day)	2.9 (1.5)	6.2 (2.7)	<0.001
Disability assessment			
Lost workdays	3.9 (2.4)	8.8 (4.0)	<0.001
Days late for work	2.6 (1.4)	4.7 (1.9)	<0.001
Days spent in bed	1.9 (0.8)	4.3 (2.0)	<0.001
Days without usual activities	4.5 (1.5)	10.9 (3.8)	<0.001

*Symptom score assessing symptom improvement: 11-point symptom score ranging from -5 (markedly worse) to +5 (markedly better).

Abbreviations used: BMI, body mass index; HIFU, high-intensity focused ultrasound; NS, not statistically significant; QoL, quality of life; USgHIFU, ultrasound-guided HIFU

Study 8 Wang Y (2018)

Details

Study type	Non-randomised prospective comparative study
Country	China (single centre)
Recruitment period	2012-13
Study population and number	n=94 (51 USgHIFU [68 fibroids] versus 43 MRlgHIFU [44 fibroids]) women with symptomatic uterine fibroids
Age and sex	USgHIFU: Mean 39 years MRlgHIFU: Mean 42 years
Patient selection criteria	Inclusion criteria: no more than 2 fibroids in each patient, determined by MRI; all fibroids hypo-intense on pre-treatment T2-weighted imaging
Technique	Each patient had only 1 session of MRgHIFU or USgHIFU treatment. The USgHIFU procedure was conducted with a JC-200 clinical extracorporeal USgHIFU system (Chongqing Haifu Tech Co, Ltd.), which was equipped with a diagnostic ultrasound (MyLab70; Esaote, Genoa, Italy) for real-time guidance. The MRgHIFU procedure was conducted with the clinical extracorporeal JM 5100 MRgHIFU system (Chongqing Haifu Tech Co, Ltd) fully integrated into a 1.5T Magnetom Avanto MRI scanner (Siemens Medical Systems) to provide a real-time temperature mapping for treatment control.
Follow-up	6 months
Conflict of interest/source of funding	The devices used for the procedures were provided by Chongqing Haifu Technical Limited Company.

Analysis

Follow-up issues: After treatment, only the patients with completely ablated fibroids (defined as 100% NPV ratio with no residual portion) were selected for further analysis.

Study design issues:

- The purpose of this study was to compare efficacy, sonication energy efficiency, treatment time and safety of MRgHIFU and USgHIFU for ablation of uterine fibroids.
- All MRgHIFU and USgHIFU procedures were conducted by 1 interventional radiologist with more than 10 years of experience in image-guided tumour ablation therapy.

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Key efficacy and safety findings

Efficacy				Safety		
Number of patients analysed: 94 (51 USgHIFU [68 fibroids] versus 43 MRigHIFU [44 fibroids])				Adverse events and complications in patients with completely ablated fibroids		
NPV ratio and NPV at 6 months				Variable	USgHIFU Group (n=22)	MRigHIFU Group (n=10)
	USgHIFU Group (% patients)	MRigHIFU Group (% patients)	p	Abnormal vaginal discharge	14% (3/22)	20% (2/10)
NPV ratio				Mild pain in the lower abdomen	9% (2/22)	30% (3/10)
100%	43% (22/51) 28 fibroids	23% (10/43) 13 fibroids	0.031	Mild lower back pain	5% (1/22)	0
90% to 99%	18% (9/51) 14 fibroids	23% (10/43) 12 fibroids	-			
Less than 90%	39% (20/51) 26 fibroids	53% (23/43) 26 fibroids	-			
NPV for completely ablated fibroids (NPV ratio=100%)						
NPV (cm³)*	118.9 ± 55.0	127.8 ± 70.2	0.632			
*Sum of fibroid's NPV in each patient.						
All patients restored normal activities within 2 hours after the procedure.						
Fibroid volume reduction and SSS at 6 months						
Variable	USgHIFU Group (n=22)	MRigHIFU Group (n=10)	p			
Mean fibroid volume reduction	52.7 ± 11.4%	59.1 ± 9.0%	NS			
Mean SSS at baseline	25.3 ± 14.7	26.6 ± 4.3				
Mean SSS at 6 months	15.1 ± 5.1	14.6 ± 2.0	NS			
Treatment time (mean ± SD)						
- USgHIFU : 114.4 ± 39.2 minutes						
- MRigHIFU: 174.5 ± 42.2 minutes						
p=0.021						
Abbreviations used: HIFU, high-intensity focused ultrasound; MRigHIFU, MRI-guided HIFU; NPV, non-perfused volume; NS, not statistically significant; SD, standard deviation; SSS, symptom severity score; USgHIFU, ultrasound-guided HIFU						

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Study 9 Kim H-K (2015)

Details

Study type	Case reports
Country	Korea
Recruitment period	2011-14
Study population and number	n= 3 women with huge uterine fibroids
Age and sex	Mean 38 years
Patient selection criteria	Women with huge uterine myoma who want to preserve fertility.
Technique	USgHIFU
Follow-up	Not reported
Conflict of interest/source of funding	None. This research was supported by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning.

Key efficacy and safety findings

Efficacy	Safety
Number of patients analysed: 3 No efficacy outcomes reported.	<p>Rapid myoma enlargement</p> <p><u>Patient 1:</u> The initial MRI before HIFU ablation showed a 15-cm-sized well-defined hypointense mass in the posterior wall of the uterine body and fundus on T2- weighted imaging. However, the follow-up MRI after 12 HIFU ablation showed a 20-cm-sized heterogeneous myoma, extending to the renal hilum level superiorly, with a large area of non-enhancing portion in T2-weighted and post-gadolinium images, suggesting degenerative change. The patient was treated with a transabdominal myomectomy.</p> <p><u>Patient 3:</u> The patient was referred to hospital complaining of abdominal discomfort due to an oversized uterine myoma. She had a history of myomectomy 10 years ago and another intramural myoma measuring 12-cm 4 years later, for which she had one time of USgHIFU ablation. Two years after the HIFU, a repeated sonogram showed marked interval increase in the size of the uterine myoma with extensively cystic degeneration. A pelvic MRI taken showed a 16-cm-sized heterogeneous mass on the anterosuperior aspect of uterine wall and a 6.8-cm-sized subserosal myoma along the left lateral wall of the uterine body. The patient was treated with a transabdominal myomectomy.</p> <p>Heavy vaginal bleeding</p> <p><u>Patient 2:</u> The patient had an USgHIFU ablation to remove a 5.5-cm-sized uterine submucosal myoma showing menorrhagia. However, 8 months after the procedure, her unusual vaginal bleeding was not resolved and her laboratory tests showed anaemia with a low hemoglobin level (5.0 mlU/L). The follow-up MRI after HIFU showed 6.1-cm-sized bulging mass with heterogeneous enhancement in the anterior wall of the uterus. The patient was treated with blood transfusions, ulipristal and an emergency uterine artery embolization.</p>
Abbreviations used: HIFU, high-intensity focused ultrasound; USgHIFU, ultrasound-guided HIFU	

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Validity and generalisability of the studies

- In Study 2, the adverse events were reported for all patients having uterine fibroids or adenomyosis.
- There was 1 RCT (study 4) included in Table 2. It compared USgHIFU with myomectomy.
- All the studies came from China apart from Study 9 which was from Korea.
- The main objective of study 6 was to evaluate the impact of USgHIFU treatment for uterine fibroids on pregnancy and pregnancy outcomes in women.
- Study 8 compared USgHIFU with MRlgHIFU.
- The longest follow-up was a median of 3 years in Study 6.

Existing assessments of this procedure

- The European Menopause and Andropause Society (EMAS) published a position statement on the management of uterine fibroids in 2014¹⁰. It says:

“8.2 Ultrasound-guided high-intensity focused ultrasound

Ultrasound-guided HIFU ablation is a new non-invasive treatment of uterine fibroids. The technique allows a check on the immediate efficacy of the procedure; then, if viable residual tissue is detected, there is the option to repeat the ablation immediately. Heterogeneous and markedly homogeneous hyperintense fibroids, as classified by MR, may be treated with ultrasound-guided HIFU. Contrast-enhanced ultrasonography may also be used to monitor gradual shrinkage of the treated fibroids or later growth. Large-scale clinical trials are needed to assess the role and limitations of these techniques.”

- The Society of Obstetricians and Gynaecologists of Canada (SOGC) published a clinical practice guideline on the management of uterine leiomyomas in 2015¹¹. It says:

“Focused Energy Delivery Systems

A number of focused energy delivery systems have been tested in the past decade including those based upon radiofrequency electricity, supercooled

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

cryoprobes, and most recently, MRg-FUS or high frequency ultrasound guided transcutaneous focused ultrasound ablation. A major disadvantage of all systems and techniques used to desiccate or ablate fibroids may be that they treat one fibroid at a time and they target the centre of fibroids, while fibroids have been shown to grow mostly from their periphery.

These technologies are relatively new and although many are promising, they often lack long-term data, which interferes with our ability to present all risks and benefits with assurance. Ongoing research and data collection are required to assess the relative merit of newer options as the technology continues to expand.”

- The College National des Gynecologues et Obstetriciens Francais published updated guidelines on the therapeutic management of uterine fibroid tumours in 2012¹². It says:

“MRI- or ultrasound-guided focused ultrasound treatment is a new possibility, and current results are encouraging, after the learning curve. Rigorous selection of patients is essential with treatment of a single fibroid or two at the most, anterior, between 5 and 12 cm, with a T2-weighted hypointense signal T2 on MRI; approximately 10% of fibroids are accessible to this technique to obtain devascularization greater than 45%, which is correlated with intermediate-term symptom relief in the order of 60–70% (LE3). On the other hand, the reduction of fibroid volume seems less substantial (15–40%) than with the other techniques (LE4). None of the current techniques can be recommended for myolysis; the technique that is most advanced, least aggressive and monitored most effectively seems to be focused ultrasound. Clinical research into these techniques must continue, with trials comparing them to surgery or uterine artery embolization, to obtain an evidence level sufficient to justify a recommendation. Patients treated with these techniques must be included in research protocols. As of today, no publication provides evidence to justify either allowing or proscribing myolysis in women who wish to become pregnant.”

Related NICE guidance

Below is a list of NICE guidance related to this procedure.

Interventional procedures

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

- Hysteroscopic morcellation of uterine leiomyomas (fibroids). NICE interventional procedures guidance 522 (2015). Available from <http://www.nice.org.uk/guidance/ipg522>
- Magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids. NICE interventional procedures guidance 413 (2011). Available from <http://www.nice.org.uk/guidance/ipg413>
- Magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids. NICE interventional procedures guidance 30 (2003). Available from <http://www.nice.org.uk/guidance/ipg30>

Additional information considered by IPAC

Specialist advisers' opinions

Specialist advice was sought from consultants who have been nominated or ratified by their Specialist Society or Royal College. The advice received is their individual opinion and is not intended to represent the view of the society. The advice provided by Specialist Advisers, in the form of the completed questionnaires, is normally published in full on the NICE website during public consultation, except in circumstances but not limited to, where comments are considered voluminous, or publication would be unlawful or inappropriate. Two Specialist Advisor Questionnaires for ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids were submitted and can be found on the [NICE website](#).

Patient commentators' opinions

NICE's Public Involvement Programme will send questionnaires to NHS trusts for distribution to patients who had the procedure (or their carers). When NICE has received the completed questionnaires, these will be discussed by the committee.

Company engagement

A structured information request was sent to 3 companies who manufacture a potentially relevant device for use in this procedure. NICE received 0 completed submission.

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Issues for consideration by IPAC

Ongoing studies

[Directed Ablation of Uterine Fibroids Using a Noninvasive Approach \(DIANA\)](#).

NCT03219385. Not yet recruiting. Case series. Estimated study completion date: September 2022. Estimated enrolment: 180 patients. USA.

[Prospective, Multi-institute, Single Arm, Confirmative Trial Evaluating Efficacy and Safety of High Intensity Focused Ultrasound Device \(RODIN\) in Women With Symptomatic Uterine Leiomyoma](#)

NCT03328260. Active. Not Recruiting. Case series. Estimated study completion date: February 2019. Actual enrolment: 34 patients. Republic of Korea.

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

References

1. Liu Y, Zhang W W, He M et al. (2019) Adverse effect analysis of high-intensity focused ultrasound in the treatment of benign uterine diseases, *International Journal of Hyperthermia*, 35:1, 56-61, DOI: 10.1080/02656736.2018.1473894
2. Chen J, Chen W, Zhang L et al. (2015) Safety of ultrasound-guided ultrasound ablation for uterine fibroids and adenomyosis: A review of 9988 cases. *Ultrasonics Sonochemistry* 27, 671-676
3. Chen J, Li Y, Wang Z, et al. (2018) Evaluation of high-intensity focused ultrasound ablation for uterine fibroids: an IDEAL prospective exploration study. *BJOG: An International Journal of Obstetrics & Gynaecology* 125(3), 354-364
4. Wang X, Qin J, Wang L et al. L (2013) Effect of high-intensity focused ultrasound on sexual function in the treatment of uterine fibroids: comparison to conventional myomectomy. *Archives of Gynecology & Obstetrics* 288(4), 851-8
5. Zhang W, He M, Huang G et al. (2016) A comparison of ultrasound-guided high intensity focused ultrasound for the treatment of uterine fibroids in patients with an anteverted uterus and a retroverted uterus. *International Journal of Hyperthermia* 32(6), 623-9
6. Li J S, Wang Y, Chen J Y et al. (2017) Pregnancy outcomes in nulliparous women after ultrasound ablation of uterine fibroids: A single-central retrospective study. *Scientific Reports* 7(1), 3977
7. Wang F, Tang L, Wang L et al. (2014) Ultrasound-guided high-intensity focused ultrasound vs laparoscopic myomectomy for symptomatic uterine myomas. *Journal of Minimally Invasive Gynecology* 21(2), 279-84
8. Wang Y, Wang Z B, and Xu Y H (2018) Efficacy, efficiency, and safety of magnetic resonance-guided high-intensity focused ultrasound for ablation of uterine fibroids: Comparison with ultrasound-guided method. *Korean Journal of Radiology* 19(4), 724-732
9. Kim H-K, Kim D, Lee M-K et al. (2015) Three cases of complications after high-intensity focused ultrasound treatment in unmarried women. *Obstetrics & Gynecology Science* 58(6), 542-6
10. Perez-Lopez F R, Ornat L, Ceausu I et al. (2014) EMAS position statement: Management of uterine fibroids. *Maturitas* 79(1), 106-116
11. Vilos GA, Allaire C, Laberge PY et al. (2015) The management of uterine leiomyomas. *Journal of Obstetrics and Gynaecology Canada*. 37(2):157-178.

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

12. Marret H, Fritel X, Ouldamer L et al. (2012). Therapeutic management of uterine fibroid tumors: updated French guidelines. European Journal of Obstetrics, Gynecology and Reproductive Biology.165(2):156-64

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Literature search strategy

Databases	Date searched	Version/files
Cochrane Database of Systematic Reviews – CDSR (Cochrane Library)	18/10/2018	Issue 10 of 12, October 2018
Cochrane Central Database of Controlled Trials – CENTRAL (Cochrane Library)	18/10/2018	Issue 9 of 12, September 2018
HTA database (CRD website)	18/10/2018	n/a
MEDLINE (Ovid)	18/10/2018	1948 to October 17, 2018
MEDLINE In-Process (Ovid) & MEDLINE ePubs ahead of print (Ovid)	18/10/2018	October 17, 2018
EMBASE (Ovid)	18/10/2018	October 17, 2018
BLIC	18/10/2018	1974 to 2018 October 17

Trial sources searched

- Clinicaltrials.gov
- ISRCTN
- WHO International Clinical Trials Registry

Websites searched

- National Institute for Health and Care Excellence (NICE)
- NHS England
- Food and Drug Administration (FDA) - MAUDE database
- Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (ASERNIP – S)
- Australia and New Zealand Horizon Scanning Network (ANZHSN)
- EuroScan
- General internet search
-

The following search strategy was used to identify papers in MEDLINE. A similar strategy was used to identify papers in other databases.

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

- 1 Uterine Neoplasms/
- 2 Leiomyoma/
- 3 Myofibroma/
- 4 Myoma/
- 5 (uter* adj4 (neoplasm* or tumour* or tumor* or growth*)).tw.
- 6 (fibroma* or myofibroma* or leiomyoma* or leimyoma* or angioleiomyoma* or angiomyoma* or myoma*).tw.
- 7 (fibromyoma* or fibroleiomyoma).tw.
- 8 ((fibroid* or myoma*) adj4 (tumour* or tumor* or uter* or submucos* subseros* or intramural* or pedunculated or cervical or cervix or womb)).tw.
- 9 or/1-8
- 10 Ultrasonic Therapy/
- 11 High-Intensity Focused Ultrasound Ablation/
- 12 (((high* adj4 intensit*) or "high* intens*" or high?-intens*) adj4 focus* adj4 ultrasound*).tw.
- 13 HIFU.tw.
- 14 or/10-13
- 15 9 and 14
- 16 (Haifu and (JC or JC200)).tw.
- 17 (Mirabilis adj4 System).tw.
- 18 (ALPIUS adj4 "900").tw.
- 19 (exAblate* adj4 "2000").tw.
- 20 or/15-19
- 21 animals/ not humans/
- 22 20 not 21
- 23 limit 22 to english language

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Appendix

The following table outlines the studies that are considered potentially relevant to the IP overview but were not included in the main data extraction table (table 2). It is by no means an exhaustive list of potentially relevant studies.

Article	Number of patients/follow-up	Direction of conclusions	Reasons for non-inclusion in table 2
Cheung V Y, Lam T P, Jenkins C R et al. (2016) Ovarian Reserve After Ultrasound-Guided High-Intensity Focused Ultrasound for Uterine Fibroids: Preliminary Experience. Journal of Obstetrics & Gynaecology Canada: JOGC 38(4), 357-61	Case series n=12 FU=1 year	Ovarian reserve does not seem to be affected by ultrasound-guided HIFU in the treatment of uterine fibroids.	Studies with more patients or longer follow-up are included.
Cho J Y, Kim S H, Kim S Y et al. (2013) Efficacy and safety of daily repeated sonographically guided high-intensity focused ultrasound treatment of uterine fibroids: preliminary study. Journal of Ultrasound in Medicine 32(3), 397-406	Case series n=24 FU=3 months	Daily repeated USgHIFU treatment of uterine fibroids may be a useful and safe method and can be used as a different option for HIFU treatment in patients who prefer treatment without anaesthesia or sedation.	Studies with more patients or longer follow-up are included.
Fruehauf J H, Back W, Eiermann A et al. (2008) High-intensity focused ultrasound for the targeted destruction of uterine tissues: experiences from a pilot study using a mobile HIFU unit. Archives of Gynecology & Obstetrics 277(2), 143-50	Case series n=12 FU=none	This study shows that a mobile ultrasound source can be used safely and effectively to destroy uterine tissues, such as fibroids, without major side effects.	Studies with more patients or longer follow-up are included.
He M, Jacobson H, Zhang C et al. (2018) A retrospective study of ultrasound-guided high intensity focussed ultrasound ablation for multiple uterine fibroids in South Africa. International Journal of Hyperthermia 34(8), 1304-1310	Retrospective case series n=81 FU=6 months	USgHIFU is safe and effective in treating patients with multiple uterine fibroids.	Studies with more patients or longer follow-up are included.
Lee J S, Hong G Y, Lee K H et al. (2017) Changes in anti-mullerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and	Prospective case series n=45 patients with uterine fibroids	USgHIFU ablation for uterine fibroid and adenomyosis was effective without affecting ovarian reserve.	Studies with more patients or longer follow-up are included.

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

uterine fibroid. BJOG: An International Journal of Obstetrics & Gynaecology 124 Suppl 3, 18-22	FU=1 year		
Lee J S, Hong G Y, Park B J et al. (2015) Ultrasound-guided high-intensity focused ultrasound treatment for uterine fibroid & adenomyosis: A single center experience from the Republic of Korea. Ultrasonics Sonochemistry 27, 682-687	Case series n=272 patients with uterine fibroids FU=1 year	USgHIFU treatment for uterine fibroid and adenomyosis is an effective non-invasive therapy via the assessment of fibroid volume reduction, symptom improvement, UFS-QOL score increase, and acceptable level of side effects. Although preliminary experience of HIFU is encouraging, well-designed prospective trials and more clinical experiences are needed to ascertain the efficacy and safety of this new treatment.	Studies with more patients or longer follow-up are included.
Leung J H, Yu S C, Cheung E C et al. (2014) Safety and efficacy of sonographically guided high-intensity focused ultrasound for symptomatic uterine fibroids: preliminary study of a modified protocol. Journal of Ultrasound in Medicine 33(10), 1811-8	Case series n=20 FU=3 months	Sonographically guided high-intensity focused ultrasound using a modified protocol may be safe and effective for symptomatic uterine fibroids in selected patients to avoid skin burns.	Studies with more patients or longer follow-up are included.
Liu Y, Ran W, Shen Y et al. (2017) High-intensity focused ultrasound and laparoscopic myomectomy in the treatment of uterine fibroids: a comparative study. BJOG: An International Journal of Obstetrics & Gynaecology 124 Suppl 3, 36-39	Non-randomised comparative study n=166 (99 USgHIFU versus 67 laparoscopic myomectomy) FU=1 year	USgHIFU can be as efficacious as laparoscopic myomectomy (LM) and effectively improve patients' quality of life in the treatment of uterine fibroids, with fewer adverse effects and complications, shorter hospital stays, and quicker postoperative recovery compared with LM.	Studies with more patients or longer follow-up are included.
Luo J, Ren X, and Yu T (2015) Efficacy of extracorporeal ultrasound-guided high intensity focused ultrasound: An evaluation based on controlled trials in China. International Journal of Radiation Biology 91(6), 480-5	Review n=518	USgHIFU should be curtailed in resectable cases and be an alternative in inoperable cases; a combination regimen should not be recommended. The Response Evaluation Criteria in Solid Tumors can be applied to HIFU.	Studies with more patients or longer follow-up are included.
Meng X, He G, Zhang J et al. (2010) A comparative study of fibroid ablation rates using radio frequency or high-intensity focused ultrasound. Cardiovascular & Interventional Radiology 33(4), 794-9	RCT n=100 (USgHIFU versus 50 RFA) FU=1 week	Radiofrequency can be applied for the majority of fibroids. As a noninvasive therapy, USgHIFU could be the preferred method for the treatment of small, hypovascular fibroids.	Studies with more patients or longer follow-up are included.
Orsi F, Monfardini L, Bonomo G et al. (2015) Ultrasound guided high intensity focused ultrasound (USgHIFU) ablation	RCT n=33 (17 contrast-enhanced)	CEUS was safe and effective in enhancing US guidance during HIFU ablation of uterine fibroids. Moreover, the use of	Studies with more patients or longer follow-up are included.

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

for uterine fibroids: Do we need the microbubbles?. International Journal of Hyperthermia 31(3), 233-9	ultrasound [CEUS] + USgHIFU versus 16 USgHIFU only) FU=1 year	CEUS during HIFU sonication increased the ablation efficacy, leading to a more relevant fibroid volume reduction at 1 and 3 months. This gap disappeared after 6 months, when there were no differences between the 2 groups of patients at MRI. However, USgHIFU represented a very effective method for the treatment of uterine fibroids, and the use of CEUS during HIFU procedure reduced the treatment time and treatment repetitions for incomplete fibroid ablation.	
Parsons J E, Lau M P. H, Martin P J et al. (2017) Pilot Study of the Mirabilis System Prototype for Rapid Noninvasive Uterine Myoma Treatment Using an Ultrasound-Guided Volumetric Shell Ablation Technique. Journal of Minimally Invasive Gynecology 24(4), 579-591	Prospective case series n=73 FU=6 months	USgHIFU ablation with the prototype device demonstrated an excellent safety profile and produced clinically relevant NPVs in a mean total treatment time of under 4 minutes using the final validated treatment settings. Short-term clinical efficacy metrics assessed in subsets of patients were encouraging, and larger studies should be conducted to confirm these results.	Studies with more patients or longer follow-up are included.
Peng S, Hu L, Chen W et al. (2015) Intraprocedure contrast enhanced ultrasound: the value in assessing the effect of ultrasound-guided high intensity focused ultrasound ablation for uterine fibroids. Ultrasonics 58, 123-8	Case series n=68 FU=post treatment	CEUS clearly showed the size of fibroids and the non-perfused areas of the fibroid. Results from CEUS correlated well with results obtained from MRI.	Studies with more patients or longer follow-up are included. There were no comparisons between pre- and post-treatment results.
Peng S, Xiong Y, Li K et al. (2012) Clinical utility of a microbubble-enhancing contrast ("SonoVue") in treatment of uterine fibroids with high intensity focused ultrasound: a retrospective study. European Journal of Radiology 81(12), 3832-8	Retrospective non-randomised comparative study n=291 (162 USgHIFU + Sonovue versus 129 USgHIFU only) FU=post-treatment	SonoVue may enhance the outcome of HIFU ablation and can be used to assess the extent of treatment.	Studies with more patients or longer follow-up are included.
Qin J, Chen J Y, Zhao W P et al. (2012) Outcome of unintended pregnancy after ultrasound-guided high-intensity focused ultrasound ablation of uterine fibroids.	Retrospective case series n=24 pregnancies	Pregnancy within 1 year after USgHIFU ablation of uterine fibroids appears safe; however, large scale studies are needed to confirm these data.	Studies with more patients or longer follow-up are included.

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

International Journal of Gynaecology & Obstetrics 117(3), 273-7	FU=1 year		
Ren X L, Zhou X D, Zhang J et al. (2007) Extracorporeal ablation of uterine fibroids with high-intensity focused ultrasound: imaging and histopathologic evaluation. Journal of Ultrasound in Medicine 26(2), 201-12	Case series n=119 FU=1 year	Imaging and histopathologic evidence directly validate USgHIFU ablation as an effective treatment of uterine fibroids.	Studies with more patients or longer follow-up are included.
Wang Y, Wang W, and Ye H (2014) Contrast-enhanced ultrasonography assessment of therapeutic efficacy for ultrasound-guided high-intensity focused ultrasound ablation of uterine fibroids: Comparison with contrast-enhanced magnetic resonance. Journal of Medical Ultrasound 22(1), 22-28	Case series n=67 FU=not reported	CEUS may be used as a convenient alternative to contrast-enhanced magnetic resonance (CEMR) in the assessment of therapeutic efficacy for USgHIFU ablation of uterine fibroids.	Studies with more patients or longer follow-up are included.
Wang Y-J, Zhang P-H, Zhang R et al. (2018) Predictive Value of Quantitative Uterine Fibroid Perfusion Parameters From Contrast-Enhanced Ultrasound for the Therapeutic Effect of High-Intensity Focused Ultrasound Ablation. Journal of Ultrasound in Medicine 04, 04	Case series n=263 FU=1 day	Quantitative parameters from CEUS are potentially useful for evaluating the therapeutic effect of HIFU ablation for uterine fibroids.	Studies with more patients or longer follow-up are included.
Wang X, Qin J, Chen J et al. (2013) The effect of high-intensity focused ultrasound treatment on immune function in patients with uterine fibroids. International Journal of Hyperthermia 29(3), 225-33	RCT n=120 (60 USgHIFU versus 60 myomectomy) FU=1 day	Short-term post-operative immune function is better preserved after USgHIFU treatment. Better preserved immune function may reflect a reduction in tissue trauma after USgHIFU treatment and contribute to reduced post-operative complications.	The main aim of this study was to evaluate the effect of USgHIFU on immune function in patients with uterine fibroids.
Wang W, Wang Y, Wang T et al. (2012) Safety and efficacy of US-guided high-intensity focused ultrasound for treatment of submucosal fibroids. European Radiology 22(11), 2553-8	Case series n=76 FU=median 30 months	USgHIFU ablation may be a safe and effective treatment for submucosal fibroids. Further studies are warranted to observe its influence on fertility.	Studies with more patients or longer follow-up are included.
Yin N, Hu L, Xiao Z B et al. (2018) Factors influencing thermal injury to skin and abdominal wall structures in HIFU ablation of uterine fibroids. International Journal of Hyperthermia 34(8), 1298-1303	Retrospective case series n=892 FU=not reported	Multiple logistic regression analysis revealed that abdominal wall thickness, total energy and abdominal wall scar were the most significant influencing factors that influenced minimal thermal injury of abdominal wall	Studies with more patients or longer follow-up are included.

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

		structures in USgHIFU ablation of uterine fibroids.	
Zhang C, Jacobson H, Ngobese Z E et al. (2017) Efficacy and safety of ultrasound-guided high intensity focused ultrasound ablation of symptomatic uterine fibroids in Black women: a preliminary study. BJOG: An International Journal of Obstetrics & Gynaecology 124 Suppl 3, 12-17	Case series n=26 FU=post-treatment	USgHIFU is feasible and safe to use to treat symptomatic uterine fibroids in Black women.	Studies with more patients or longer follow-up are included.
Zhao W-P, Zhang J, Han Z-Y, et al. (2017) A clinical investigation treating different types of fibroids identified by MRI-T2WI imaging with ultrasound guided high intensity focused ultrasound. Scientific Reports 7(1), 10812	Retrospective case series n=172 FU=1 year	USgHIFU ablation of all types of fibroids were safe and effective.	Studies with more patients or longer follow-up are included.
Zhao W P, Chen J Y, and Chen W Z (2016) Dynamic contrast-enhanced MRI serves as a predictor of HIFU treatment outcome for uterine fibroids with hyperintensity in T2-weighted images. Experimental and Therapeutic Medicine 11(1), 328-334	Retrospective case series n=131 FU=post-treatment	Hyperintense uterine fibroids with slight and irregular enhancement in the arterial phase of dynamic contrast-enhanced MRI are suitable for USgHIFU treatment. By contrast, uterine fibroids with regular enhancement were associated with the lowest treatment efficacy and safety.	Studies with more patients or longer follow-up are included.
Zhao W P, Han Z Y, Zhang J et al. (2015) A retrospective comparison of microwave ablation and high intensity focused ultrasound for treating symptomatic uterine fibroids. European Journal of Radiology 84(3), 413-417	Retrospective comparative study n=73 (42 USgHIFU versus 31 MWA) FU=6 months	The safety and effectiveness of percutaneous MWA and USgHIFU in the treatment of uterine fibroids were similar; however, the median treatment time of PMWA was shorter than that of USgHIFU.	Studies with more patients or longer follow-up are included.
Zhao W P, Chen J Y, Zhang L et al. (2013) Feasibility of ultrasound-guided high intensity focused ultrasound ablating uterine fibroids with hyperintense on T2-weighted MR imaging. European Journal of Radiology 82(1), e43-9	Retrospective case series n=282 FU=1 month	The heterogeneous and markedly homogeneous hyperintense fibroids were suitable for USgHIFU, and only the slightly homogeneous hyperintense fibroids should be excluded.	Studies with more patients or longer follow-up are included.
Zhou X D, Ren X L, Zhang J et al. (2007) Therapeutic response assessment of high intensity focused ultrasound therapy for uterine fibroid: utility of contrast-enhanced ultrasonography. European	Case series n=64 FU=1 year	CEUS is potentially useful for evaluating the early therapeutic effect of percutaneous HIFU ablation for uterine fibroids.	Studies with more patients or longer follow-up are included.

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Journal of Radiology 62(2), 289-94			
Zou M, Chen L, Wu C et al. (2017) Pregnancy outcomes in patients with uterine fibroids treated with ultrasound-guided high-intensity focused ultrasound. BJOG: An International Journal of Obstetrics & Gynaecology 124 Suppl 3, 30-35	Retrospective case series n=78 FU = 18 months	USgHIFU treatment can effectively treat patients with uterine fibroids who wish to have children; it could significantly reduce the preparation period for pregnancy after the operation. It can also improve the fertility of patients with a history of infertility and abnormal pregnancy and child-bearing, with no additional obstetric risks.	Studies including pregnancy outcomes after USgHIFU are already included.
<i>Ultrasound-guided High Intensity Focused Ultrasound Ablation for Symptomatic Uterine Fibroids: A Preliminary Clinical Experience. Ultraschall in der Medizin / European Journal of Ultrasound. [Paper accepted for publication].</i>	<i>Prospective case series</i> <i>Single centre in the NHS</i> n=12 FU=2 years	<ul style="list-style-type: none"> • <i>No serious adverse events were reported, but a second-degree skin burn was observed in 1 patient who had a surgical scar from a previous caesarean section.</i> • <i>Mean symptom severity scores (SSS-QOL) improved significantly from 56.5±29.1 at baseline to 33.4±23.3 (p<0.01) at 3 months, 45.0±35.4 (p<0.05) at 1 year and 40.6±32.7 (p<0.01) at 2 years post-treatment.</i> • <i>Mean non-perfused volume ratio was 67.7±39.0% in the treated fibroids (n=14) within 3 months after treatment.</i> • <i>Mean volume reduction rates of the treated fibroids were 23.3±25.5% at 3 months post-treatment (p<0.01, n=14), 49.3±23.7% at 12 months (p<0.05, n=8), and 51.9±11.1% at 24 months (p<0.005, n=8).</i> 	<i>Studies with more patients or longer follow-up are included.</i>

IP overview: ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids